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FIGURE 2 
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FIGURE 3A 
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FIGURE 4B 
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FIGURE SB 
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FIGURE 6 
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FIGURE 7B 
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FIGURE 7C 
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FIGURE 8A 
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FIGURE 9B 
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FIGURE 10 
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1. 
CROSS-CONUGATED 
2.5-CYCLOHEXADIENONE AND RELATED 
SYNTHESIS METHODS 
This application for patent under 35 U.S.C. S 111 (a) claims 5 
priority to Provisional Application(s) Ser. No. 61/177,500 
filed on May 12, 2009 under 35 U.S.C. S 111(b). 
FIELD OF THE INVENTION 
1C 
The present invention relates to methods for the synthesis 
of galanthamine, morphine and precursors, intermediates, 
and derivatives thereof. In preferred embodiments, the inven 
tion relates to methods for improving the efficiency and over 
all yield of said morphine, morphine related derivatives and 15 
intermediates thereof. In further embodiments, the invention 
relates to methods for improving the efficiency and overall 
yield of galanthamine and intermediates thereof. 
BACKGROUND OF THE INVENTION 2O 
Morphine is one of the most important analgesics world 
wide. The majority of the world's morphine supply is derived 
from poppy plants found in Some of the more politically 
turbulent areas of western Asia. A related compound, galan 
thamine, has shown efficacy in the treatment of inter alia, 25 
Alzheimer's disease. However, while morphine remains in 
high demand worldwide, the lack of effective synthetic meth 
ods coupled with the aforementioned instability in areas 
largely responsible for the natural production of morphine 
illustrates the tenuous state of current means for obtaining the 30 
compound. Similarly, overall yields for galanthamine using 
current synthetic routes remain poor. Thus, there is a need to 
develop improved methods for synthesizing morphine and 
related derivatives for use in pharmaceutical compositions 
and other medical applications. 35 
SUMMARY OF THE INVENTION 
The present invention relates to methods and compositions 
for the synthesis of galanthamine, morphine and precursors, 
intermediates (including but not limited to codeine), salts, 
and derivatives thereof. In addition, pharmaceutical formula 
tions comprising Such compositions, as well as methods of 
treatment comprising administering said compositions), are 
contemplated. In preferred embodiments, the invention 
relates to methods for improving the efficiency and overall 45 
yield of said morphine, morphine related derivatives and 
intermediates thereof, as well as the resulting compositions 
for pharmaceutical formulations and human treatment (e.g. to 
relieve or prevent pain, to Suppress coughing, etc.). In further 
embodiments, the invention relates to methods for improving 50 
the efficiency and overall yield of galanthamine and interme 
diates thereof, as well as the resulting compositions for phar 
maceutical formulations and human treatment (e.g. mild to 
moderate Alzheimer's). In addition, the methods permit the 
further efficient synthesis of galanthamine derivatives, such 
as N-alkyl galanthamine derivatives e.g. N-allylnorgalan 
thamine, N-(14-methylallyl)norgalanthamine, etc., see FIG. 
10, which are more potent cholinesterase inhibitors than 
galanthamine. 
In addition, atoms making up the compounds of the present 
invention are intended to include all isotopic forms of such 
atoms. Isotopes, as used herein, include those atoms having 
the same atomic number but different mass numbers. By way 
of general example and without limitation, isotopes of hydro 
gen include tritium and deuterium, and isotopes of carbon 
include 'Cand C. Similarly, it is contemplated that one or 65 
more carbon atom(s) of a compound of the present invention 





templated that one or more oxygenatom(s) of a compound of 
the present invention may be replaced by a Sulfur or selenium 
atom(s). 
Other non-carbon groups contemplated by the present 
invention as candidates for Substituting into the compounds 
described herein include, but are not limited to oxy, amino, 
amido, imino, thio, thiol, Sulfonyl, ammonium, Sulfonium, 
silyl and the Substituted versions of these groups. 
In some embodiments the terms alkyl, aryl, alkanediyl. 
alkynyl, arenediyl, aralkyl, heteroarenediyl, heteroaralkyl, 
heteroaryl, alkenyl, alkenediyl, alkynediyl, acyl, alkylidene, 
or a Substituted version of any of these groups, refer to groups 
with a number of carbons s20. In some embodiments the 
terms alkyl, aryl, alkanediyl, alkynyl, arenediyl, aralkyl, het 
eroarenediyl, heteroaralkyl, heteroaryl, alkenyl, alkenediyl. 
alkynediyl, acyl, alkylidene, or a Substituted version of any of 
these groups, refer to groups with a number of carbons is 12. 
In some embodiments the terms alkyl, aryl, alkanediyl, alky 
nyl, arenediyl, aralkyl, heteroarenediyl, heteroaralkyl, het 
eroaryl, alkenyl, alkenediyl, alkynediyl, acyl, alkylidene, or a 
Substituted version of any of these groups refer to groups with 
a number of carbons s10. In some embodiments the terms 
alkyl, aryl, alkanediyl, alkynyl, arenediyl, aralkyl, heteroare 
nediyl, heteroaralkyl, heteroaryl, alkenyl, alkenediyl. 
alkynediyl, acyl, alkylidene, or a Substituted version of any of 
these groups, refer to groups with a number of carbons s8. In 
Some embodiments, the present invention contemplates allyl, 
propargyl, and cyclopropyl carbinol derivatives. 
In some embodiments (FIG.3A), the invention relates to a 
method for forming a cross-conjugated 2.5-cyclohexadi 
enone, comprising i) providing a substituted biphenyl; ii) 
treating said biphenyl to create an ether. In further embodi 
ments, said biphenyl is treated with an alkenylether or 
vinylether (e.g. ethylvinyl ether) under a set of conditions to 
create a biphenyl ether. In one embodiment, the method fur 
ther comprises iii) treating said ether under conditions (e.g. 
with a phenol alkylating catalyst) to cause intramolecular 
phenol alkylation so as to produce a cross-conjugated 2.5- 
cyclohexadienone (or derivative thereof). In further embodi 
ments, said Substituted biphenyl is produced in a Suzuki 
coupling reaction. In still further embodiments, said Substi 
tuted biphenyl is produced in an Ullman coupling reaction. In 
still further embodiments said substituted biphenyl ether is 
treated under a second set of conditions to form a cross 
conjugated 2,5-cyclohexadienone derivative. Some generic 
embodiments are shown in FIG. 3A. Some specific non 
limiting examples of contemplated derivatives are shown in 
FIG. 3B. In additional embodiments, said substituted biphe 
nyl has the structure: 
HO CHO 
OR 
wherein Z is H or RO, wherein R is an alkyl, aryl or het 
eroaryl group or the like (i.e. other groups such as alkanediyl. 
alkynyl, arenediyl, aralkyl, heteroarenediyl, heteroaralkyl, 
alkenyl, alkenediyl, alkynediyl, acyl, alkylidene, non-carbon 
group, or a substituted version of any of these groups), a 
protecting group, but not H, and R is a protecting group or H. 
In some embodiments, said protecting group is selected from 
the group consisting of triisopropylsilyl and tert-butyldimeth 
ylsilyl. In further embodiments, said ether has the structure: 




wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like a protecting group but not H. R. 
is a protecting group or H. R. can be alkyl or aryl or the like 
(i.e. other groups such as alkanediyl, alkynyl, arenediyl. 
aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alkenyl, 
alkenediyl, alkynediyl, acyl, alkylidene, non-carbon group, 
or a substituted version of any of these groups); and X is a 
halide or an equivalent leaving group. Some generic embodi 
ments are shown in FIG. 3A. Some specific non-limiting 
examples of contemplated derivatives are shown in FIG. 3B. 
In further embodiments, said cross-conjugated 2.5-cyclo 




wherein R is an alkyl, aryl, or heteroaryl group or the like or 
a protecting group but not H; and R is a protecting group or 
H. At this point, the synthesis can be directed to galanthamine 
or to morphine (the steps leading to morphine will be 
described here and the steps leading to galanthamine will be 
described below). In one embodiment where the synthesis 
proceeds to morphine, the method further comprises iv) treat 
ing the cross-conjugated 2.5-cyclohexadienone of step iii) 
with a nitroalkane under Henry reaction conditions so as to 
create a dihydro-1H-phenanthren-2-one derivative. In addi 
tional embodiments, said dihydro-1H-phenanthren-2-one 
derivative is a nitroalkene. In additional embodiments, said 
dihydro-1H-phenanthren-2-one derivative is a B-hydroxy 
nitroalkane. Some generic embodiments are shown in FIG. 
4A. Some specific non-limiting examples of contemplated 
derivatives are shown in FIG. 4B. In some embodiments, said 




wherein R is an alkyl, aryl or heteroaryl group or the like or 












like (i.e. other groups such as alkanediyl, alkynyl, arenediyl. 
aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alkenyl, 
alkenediyl, alkynediyl, acyl, alkylidene, non-carbon group, 
or a Substituted version of any of these groups). Some generic 
embodiments are shown in FIG. 4A. Some specific non 
limiting examples of contemplated derivatives are shown in 
FIG. 4B. In some embodiments, said nitroalkane has the 
Structure 
wherein R is an alkyl, aryl or heteroaryl group or the like 
or a protecting group but not H; R can be alkyl or aryl or the 
like, and R, can be H, alkyl, aryl, or heteroaryl group or the 
like (i.e. other groups such as alkanediyl, alkynyl, arenediyl. 
aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alkenyl, 
alkenediyl, alkynediyl, acyl, alkylidene, non-carbon group, 
or a substituted version of any of these groups). In further 
embodiments, said dihydro-1H-phenanthren-2-one deriva 
tive is in the form of a mixture of epimers. In some embodi 
ments, the invention further comprises V) treating said 
nitroalkene with a (mild) reducing agent so as to create 
nitroalkane. Some generic embodiments are shown in FIG. 
4A. Some specific non-limiting examples of contemplated 
derivatives are shown in FIG. 4B. It is noteworthy that only 
the correct cis-stereochemical relationship between the 
newly formed B-ring and the C-ring, i.e. at the C and Ca 
positions, is observed in 15. In further embodiments, said 
nitroalkane has the structure 
RO 
RO 
wherein R is an alkyl, aryl, or heteroaryl group or a protect 
ing group but not H. R. can be alkyl or aryl or the like; and R, 
can be H, alkyl, aryl, heteroaryl group or the like. In still 
further embodiments, said nitroalkane is in the form of a 
mixture of epimers. In additional embodiments, the invention 
further comprises vi) treating said nitroalkane with a reducing 
agent so as to create a primary amine. Some generic embodi 
ments are shown in FIG. 4A. Some specific non-limiting 
examples of contemplated derivatives are shown in FIG. 4B. 
In some embodiments, said amine has the structure 
  
US 8,362,283 B2 
OH 
wherein R is an alkyl, aryl, or heteroaryl group or the like or 
a protecting group but not H. R. can be alkyl/aryl or the like; 
and R, can be H, alkyl, aryl, heteroaryl group or the like. In 
Some embodiments, the invention further comprises vii) 
treating said primary amine with a (mild) reducing agent so as 
to create a secondary amine. In further embodiments, said 
secondary amine is the result of intramolecular reductive 
amination. Some generic embodiments are shown in FIG. 4A. 
Some specific non-limiting examples of contemplated deriva 
tives are shown in FIG. 4B. In still further embodiments, said 
secondary amine has the structure 
wherein R is an alkyl, aryl, or heteroaryl group or the like, a 
protecting group or H; and R, can be H or an alkyl, aryl, or 
heteroaryl group or the like. In additional embodiments, the 
invention further comprises viii) treating said secondary 
amine with base so as to create a carbamate derivative. Some 
generic embodiments are shown in FIG. 4A. Some specific 
non-limiting examples of contemplated derivatives are shown 
in FIG. 4B. In some embodiments, said carbamate derivative 
has the structure 
wherein R is an alkyl, aryl, heteroaryl group or the like, a 













group or the like; and Rs is an alkyl, aryl, or heteroaryl group 
or the like (i.e. other groups such as alkanediyl, alkynyl, 
arenediyl, aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, 
alkenyl, alkenediyl, alkynediyl, acyl, alkylidene, non-carbon 
group, or a Substituted version of any of these groups). In 
further embodiments, the invention further comprises ix) 
treating said carbamate derivative with a halohydantoin so as 
to create a halohydrin. In still further embodiments, said 
halohydantoin is 2.2 bromo-3.5 dimethylhydantoin and said 
halohydrin is a bromohydrin. Some generic embodiments are 
shown in FIG. 5A. Some specific non-limiting examples of 
contemplated derivatives are shown in FIG. 5B. In additional 
embodiments, said bromohydrin has the structure 
wherein R is an alkyl, aryl, or heteroaryl group or the like, a 
protecting group or H. R., is Horan alkyl, aryl, or heteroaryl 
group or the like; and Rs is an alkyl, aryl, or heteroaryl group 
or the like. 
In additional embodiments, the invention further com 
prises viii) treating said secondary amine with carbon-halide 
So as to create a tertiary amine derivative. Some generic 
embodiments are shown in FIG. 4A. Some specific non 
limiting examples of contemplated derivatives are shown in 
FIG. 4B. In some embodiments, said tertiary amine derivative 
has the structure 
wherein R is an alkyl, aryl, heteroaryl group or the like, a 
protecting group, or H. R, is Horan alkyl, aryl, or heteroaryl 
group or the like; and Rs is an alkyl, aryl, or heteroaryl group 
or the like (i.e. other groups such as alkanediyl, alkynyl, 
arenediyl, aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, 
alkenyl, alkenediyl, alkynediyl, acyl, alkylidene, non-carbon 
group, or a substituted version of any of these groups). 
In some embodiments, further comprising X) treating said 
halohydrin with base so as to create an epoxide. Some generic 
embodiments are shown in FIG. 5A. Some specific non 
limiting examples of contemplated derivatives are shown in 
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wherein R is an alkyl, aryl, or heteroaryl group or the like or 
a protecting group, or H; R is Horan alkyl, aryl, or heteroaryl 
group or the like; Rs is an alkyl, aryl, or heteroaryl group or 
the like; and X is a halide or an equivalent leaving group. This 
epoxide is a novel compound and an important compound, 
since it allows access to a large range of derivatives (including 
but not limited to 7-alkyl (or aryl, etc.) derivatives of 
codeine); the present invention contemplates this 6.7-alpha 
epoxide as a composition of matter and in methods for Syn 
thesizing downstream derivatives (including but not limited 
to 7-fsubstituted 7,8-dihydro derivatives) as pharmaceutical 
formulations for human treatment. Some specific non-limit 
ing examples of contemplated derivatives are shown in FIG. 
9B. In still further embodiments, the invention further com 
prises Xi) treating said epoxide with a reducing agent in the 
presence of an organic disulfide so as to create a carbo Sulfide. 
Some generic embodiments are shown in FIG. 5A. Some 
specific non-limiting examples of contemplated derivatives 
are shown in FIG. 5B. In additional embodiments, said carbo 
sulfide has the structure 
wherein R is an alkyl, aryl, or heteroaryl group or the like, or 
a protecting group, or H. R-7 is an H or an alkyl, aryl, or 
heteroaryl group or the like; Rs is an alkyl, aryl, or heteroaryl 
group or the like; R is an alkyl, aryl, or heteroaryl group or 
the like (i.e. other groups such as alkanediyl, alkynyl, arene 
diyl, aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alk 
enyl, alkenediyl, alkynediyl, acyl, alkylidene, non-carbon 
group, or a Substituted version of any of these groups); and X 
is a halide or an equivalent leaving group. In still further 
embodiments, the invention further comprises Xi) treating 
said epoxide with a reducing agent in the presence of an 
organic disulfide so as to create a phenyl Sulfide. Some 
generic embodiments are shown in FIG. 5A. Some specific 
non-limiting examples of contemplated derivatives are shown 
in FIG. 5B. In additional embodiments, said phenyl sulfide 













wherein R is an alkyl, aryl, or heteroaryl group or the like, or 
a protecting group, or H. R-7 is an H or an alkyl, aryl, or 
heteroaryl group or the like; Rs is an alkyl, aryl, or heteroaryl 
group or the like; and X is a halide or an equivalent leaving 
group. In additional embodiments, the invention further com 
prises xii) treating said phenylsulfide with an oxidizing agent 
(preferably hydrogen peroxide) in the presence of an acidic 
alcohol Such as a halogenated alcohol (preferably hexafluor 
oisopropanol) so as to create a Sulfoxide. Some generic 
embodiments are shown in FIG. 9A. Some specific non 
limiting examples of contemplated derivatives are shown in 
FIG.9B. In one embodiment, said sulfoxide has the structure: 
wherein R is an alkyl, aryl, or heteroaryl group or the like, or 
a protecting group, or H. R-7 is an H or an alkyl, aryl, or 
heteroaryl group or the like; Rs is an alkyl, aryl, or heteroaryl 
group or the like; R is an alkyl, aryl, or heteroaryl group or 
the like; and X is a halide or an equivalent leaving group. In 
further embodiments, the invention further comprises xiii) 
heating said Sulfoxide to give anallylic alcohol. Some generic 
embodiments are shown in FIG. 5A. Some specific non 
limiting examples of contemplated derivatives are shown in 
FIG. 5B. In some embodiments, said allylic alcohol has the 
Structure 
wherein R is an alkyl, aryl, or heteroaryl group or the like, or 
a protecting group, or H. R-7 is an H or an alkyl, aryl, or 
heteroaryl group or the like; Rs is an alkyl, aryl, or heteroaryl 
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group. In further embodiments, the invention further com 
prises xiv) treating said allylic alcohol with a reducing agent 
so as to create codeine. In still further embodiments, the 
invention further comprises XV) treating said codeine with a 
(preferably strong) Lewis acid so as to create morphine. 
In still further embodiments, the invention further com 
prises treating said epoxide with a Grignard reagent so as 
yield an epoxide ring opened 6-hydroxy,7-adduct. Some 
generic embodiments are shown in FIG. 9A. Some specific 
non-limiting examples of contemplated derivatives are shown 
in FIG. 9B. In additional embodiments, said epoxide ring 
opened 6-hydroxy,7-adduct has the structure 
wherein R is an alkyl, aryl, or heteroaryl group or the like, or 
a protecting group, or H. R, is an H or an alkyl, aryl, or 
heteroaryl group or the like; Rs is an alkyl, aryl, or heteroaryl 
group or the like Rio is an alkyl, aryl, or heteroaryl group or 
the like (i.e. other groups such as alkanediyl, alkynyl, arene 
diyl, aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alk 
enyl, alkenediyl, alkynediyl, acyl, alkylidene, non-carbon 
group, or a Substituted version of any of these groups) or H: 
and X is a halide or an equivalent leaving group. 
In some embodiments, the invention relates to a composi 
tion of the formula (or salt thereof): 
HO CHO 
OR 
wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like or a protecting group, but not H: 
R is a protecting group. In one embodiment, the protecting 
group is selected from a group consisting of triisopropylsilyl 
and tert-butyldimethylsilyl, and (in general) SiRRRs where 
R can be alkyl, aryl, or the like (i.e. other groups such as 
alkanediyl, alkynyl, arenediyl, aralkyl, heteroarenediyl, het 
eroaralkyl, heteroaryl, alkenyl, alkenediyl, alkynediyl, acyl, 
alkylidene, non-carbon group, or a Substituted version of any 
of these groups), R can be alkyl, aryl, or the like (i.e. other 
groups such as alkanediyl, alkynyl, arenediyl, aralkyl, het 
eroarenediyl, heteroaralkyl, heteroaryl, alkenyl, alkenediyl. 
alkynediyl, acyl, alkylidene, non-carbon group, or a Substi 













aryl, or the like (i.e. other groups such as alkanediyl, alkynyl, 
arenediyl, aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, 
alkenyl, alkenediyl, alkynediyl, acyl, alkylidene, non-carbon 
group, or a Substituted version of any of these groups). In 
further embodiments, the inventions relates to a composition 




wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like or a protecting group, but not H: 
R is a protecting group or H; R can be alkyl or aryl or the 
like; and X is a halide or an equivalent leaving group. In still 
further embodiments, the invention relates to a composition 




wherein Zis Hor RO, wherein R is an alkyl, aryl, heteroaryl 
group or the like, or a protecting group, or H; and R is a 
protecting group. In additional embodiments, the invention 
relates to a composition of the formula (or salt thereof): 
RO NO 
O 
wherein Zis Hor RO, wherein R is an alkyl, aryl, heteroaryl 
group or the like or a protecting group, or H; and R can be 
alkyl or aryl or the like (i.e. other groups such as alkanediyl. 
alkynyl, arenediyl, aralkyl, heteroarenediyl, heteroaralkyl, 
heteroaryl, alkenyl, alkenediyl, alkynediyl, acyl, alkylidene, 
non-carbon group, or a Substituted version of any of these 
groups). In some embodiments, the invention relates to a 
composition of the formula (or salt thereof): 
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wherein Z is Hor RO, wherein R is an alkyl, aryl, heteroaryl 
group or the like or a protecting group, or H; R can be alkyl, 
aryl or the like; and R, can be H, alkyl, aryl, or heteroaryl 
group or the like. In further embodiments, the invention 
relates to a composition of the formula (or salt thereof): 
wherein Zis Hor RO, wherein R is an alkyl, aryl, heteroaryl 
group or the like or a protecting group, or H; R can be alkyl, 
aryl, or the like; and R, can be H, alkyl, aryl or heteroaryl 
group, or the like. In still further embodiments, the invention 
relates to a composition of the formula (or salt thereof): 
OH 
wherein Zis Hor RO, wherein R is an alkyl, aryl, heteroaryl 
group or the like or a protecting group, or H; R can be alkyl, 
aryl, or the like; and R, can be H, alkyl, aryl, or heteroaryl 
group or the like. In additional embodiments, the invention 













wherein Zis Hor RO, wherein R is an alkyl, aryl, heteroaryl 
group or the like or a protecting group, or H; and R, can be H 
or an alkyl, aryl, or heteroaryl group, or the like. In some 
embodiments, the invention relates to a composition of the 
formula (or salt thereof): 
wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like or a protecting group, or H. R., is 
Horan alkyl, aryl, or heteroaryl group or the like; and Rs is an 
alkyl, aryl, or heteroaryl group or the like. In further embodi 
ments, the invention relates to a composition of the formula 
(or salt thereof): 
wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like or a protecting group, or H. R, is 
H or an alkyl, aryl, or heteroaryl group or the like; Rs is an 
alkyl, aryl, or heteroaryl group or the like; and X is a halide or 
an equivalent leaving group. In still further embodiments, the 
invention relates to a composition of the formula (or salt 
thereof): 
wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like or a protecting group, or H. R, is 
H or an alkyl, aryl, or heteroaryl group or the like; Rs is an 
alkyl, aryl, or heteroaryl group or the like; and X is a halide or 
an equivalent leaving group. In additional embodiments, the 
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wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like or a protecting group, or H. R, is 
H or an alkyl, aryl, or heteroaryl group or the like; Rs is an 
alkyl, aryl, or heteroaryl group or the like; R is an alkyl, aryl, 
or heteroaryl group or the like; and X is a halide or an equiva 
lent leaving group. In some embodiments, the invention 
relates to a composition of the formula (or salt thereof): 
wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like or a protecting group, or H. R, is 
H or an alkyl, aryl, or heteroaryl group or the like; Rs is an 
alkyl, aryl, or heteroaryl group or the like; R is an alkyl, aryl, 
or heteroaryl group or the like; and X is a halide or an equiva 
lent leaving group. In further embodiments, the invention 
relates to a composition of the formula (or salt thereof): 
NCOR8 
w w HO 
wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or the like or a protecting group or H, or H: 
R, is Horan alkyl, aryl, or heteroaryl group or the like; Rs is 
an alkyl, aryl, or heteroaryl group or the like; and X is a halide 
or an equivalent leaving group. In still further embodiments, 















In additional embodiments, the invention relates to a compo 
sition of the formula (or salt thereof): 
O 
In some embodiments, the invention relates to a method of 
synthesizing a compound comprising:) mixing 4-bromophe 
nol, imidazole and 1,2-dichloroethane at a temperature 
between 20° C. and 25°C., preferably 23°C., to form a first 
Solution, mixing triisopropylsilylchloride with said first solu 
tion for at least 10 hours, preferably at least 11 hours and more 
preferably 12 hours, to form a second mixture, transferring 
said second mixture to an aqueous NHCl to form a third 
solution, combining said third solution with CHCl to form 
a fourth solution, combining said fourth solution with a brine 
solution to form a fifth solution, mixing said fifth solution 
with NaSO, separating said fifth solution from said NaSO 
to give a sixth solution, reducing the Volume of said sixth 
Solution using a means for reducing said Volume, and recov 
ering said compound. In further embodiments, said means for 
reducing Volume is a vacuum system. In still further embodi 
ments, said compound is: 
Br 
OR 
In further embodiments, R is selected from the group consist 
ing of-TIPS (triisopropylsilyl) and -TBDMS (tert-butyldim 
ethylsilyl). In additional embodiments, the percent yield of 
said compound is at least 95%, preferably at least 97% and 
more preferably 99%. 
In some embodiments, the invention relates to a method of 
synthesizing a compound comprising: mixing isovanillin, 





US 8,362,283 B2 
15 
and argon gas to form a first solution, combining a bromine 
Solution further comprising acetic acid with said first Solution 
to form a second solution, combining said second Solution 
with water maintained at a temperature between 0°C. and 10° 
C. to form a third solution, filtering said third solution, reduc 
ing the Volume of said third solution using a means for reduc 
ing said Volume, and recovering said compound. In further 
embodiments, said means for reducing Volume is a vacuum 




In additional embodiments, the percent yield of said com 
pound is at least 75%, preferably at least 77% and more 
preferably 79% or more. 
In some embodiments, the invention further comprises: 
mixing (4-bromo-phenoxy)-triisopropylsilane and THF at a 
temperature of at least -75°C., preferably -78°C. to form a 
first solution, mixing said first solution with a composition 
comprising n-Bulli further comprising THF to form a second 
Solution, stirring said second solution for at least 60 minutes, 
preferably 70 minutes, at a temperature of at least -75° C. 
more preferably -78°C., mixing said second solution with a 
solution of B(OPr') to formathird solution, stirring said third 
mixture for at least 10 hours, preferably at least 11 hours and 
more preferably 12 hours, at a temperature of at least 20°C., 
preferably 23°C., mixing said third mixture with a solution 
comprising 10% aqueous KHSO to form a fourth solution, 
mixing said fourth solution with EtOAc to form a fifth solu 
tion, mixing said fifth solution with a brine solution to form a 
sixth solution, i) mixing said sixth solution with NaSO, 
reducing the Volume of said sixth solution using a means for 
using a means for reducing said Volume to obtain a first Solid, 
purifying said first solid using a first means for purification to 
form a second Solid, mixing said second Solid with toluene, 
and recovering said compound. In further embodiments, said 
means for reducing Volume is a vacuum system. In still fur 
ther embodiments, said compound is: 
B B 
A1 No1 NA 
In even further embodiments, Aris: 
OTIPS 
In additional embodiments, the percent yield of said com 
pound is at least 75%, preferably 76% or more. 
In some embodiments, the invention further comprises: 
mixing 1,4-dioxane, water, KCOs, 2,6-di-tert-butyl-4 meth 
ylphenol, and tricyclohexylphoshine to form a first solution, 
stirring said first solution for at least 10 minutes, preferably 
15 minutes at a temperature of at least 20°C., preferably 23° 













ond solution, refluxing said second solution for at least 45 
minutes, preferably 55 minutes and more preferably 60 min 
utes, mixing said second solution with aqueous NHCl to 
form a third solution, mixing said third solution with EtOAc 
to form a fourth Solution, mixing said fourth solution with a 
brine solution to form a fifth solution, mixing said fifth solu 
tion with Na2SO4, separating said fifth solution from said 
Na2SO, reducing the Volume of said fifth solution using a 
means for reducing said Volume, and recovering said com 
pound. In further embodiments, said means for reducing Vol 





In additional embodiments, R is TIPS. In some embodiments, 
the percent yield of said compound is at least 85%, preferably 
at least 95% and more preferably 96%. In some embodi 
ments, the invention relates to a method for synthesizing a 
compound comprising: mixing bromine and CH2Cl at a tem 
perature of 0° C. to form a first solution, mixing said first 
solution with ethyl vinyl ether to form a second solution, 
stirring said second solution for at least 15 minutes, prefer 
ably 20 minutes, at 0°C., mixing said second solution with 
N,N-diisopropylamine to form a third solution, mixing said 
third solution with a mixture comprising CHCl to form a 
fourth solution, stirring said fourth solution for at least 10 
hours, preferably at least 11 hours and more preferably 12 
hours, at a temperature of at least 20°C., more preferably 23° 
C., mixing said fourth solution with Saturated aqueous 
NaHCO, to form a fifth solution, mixing said fifth solution 
with CHCl to form a sixth solution, mixing said sixth solu 
tion with a brine solution to form a seventh solution, mixing 
said seventh solution with NaSO4, separating said seventh 
solution from said NaSO, reducing the Volume of said sev 
enth Solution using a means for reducing said Volume, and 
recovering said compound. In further embodiments, said 
means for reducing Volume is a vacuum system. In still fur 






In additional embodiments, R is TIPS. In some embodiments, 
the percent yield of said compound is at least 95%, preferably 
at least 97% and more preferably at least 99%. 
In some embodiments, the invention further comprises: 
mixing CsF and DMF to form a first solution, refluxing said 
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first solution for at least one hour, mixing said first mixture 
with saturated aqueous NaHCO, to form a second mixture, 
mixing said second mixture with EtOAc to form a third mix 
ture, mixing said third solution with a brine solution to form 
a fourth solution, mixing said fourth solution with NaSO 
separating said fourth solution from said Na2SO, reducing 
the Volume of said fourth solution using a means for reducing 
said Volume, and recovering said compound. In further 
embodiments, said means for reducing Volume is a vacuum 





In still further embodiments, the percent yield of said com 
pound is at least 80%, preferably at least 85% and more 
preferably 90% or more. 
In some embodiments, the invention further comprises: 
adding nitromethane to form a first solution, mixingNHOAC 
and acetic acid with said first Solution to form a second 
Solution, refluxing said second solution for at least one hour, 
preferably two hours, mixing said second solution with a 
brine solution to form a third solution comprising an aqueous 
layer and a non-aqueous layer, removing said aqueous layer 
from said third solution, mixing said aqueous layer with ether 
to form a fourth solution, mixing said fourth layer with 
Na2SO, separating said fourth layer from said Na2SO4. 
reducing the Volume of said fourth Solution using a means for 
reducing said Volume, and recovering said mixture of com 
pounds. In further embodiments, said means for reducing 
Volume is a vacuum system. In still further embodiments, said 
mixture of compounds comprises: 
MeO 
O O 


















In additional embodiments, the percent yield of said mixture 
of compounds is at least 50%, preferably 90% and more 
preferably 97% or more. 
In some embodiments, the invention further comprises: 
mixing THF and phosphate buffer to form a first solution, 
mixing said first solution with NaBHCN at a temperature of 
0° C. to form a second solution, stirring said second solution 
for at least 30 minutes, preferably 45 minutes and more pref 
erably 60 minutes, mixing said second solution with aqueous 
NHCl to form a third solution, mixing said third solution 
with EtOAc to form a fourth solution, mixing said fourth 
solution with a brine solution to form a fifth solution, mixing 
said fifth solution with NaSO, separating said fifth solution 
from said NaSO, reducing the volume of said fifth solution 
using a means for reducing said Volume, and recovering said 
mixture of compounds. In further embodiments, said means 
for reducing Volume is a vacuum system. In still further 
embodiments, said mixture of compounds comprises: 
In additional embodiments, the percent yield of said mixture 
of compounds is at least 80%, preferably at least 85% and 
more preferably at least 88%. In some embodiments, the 
invention further comprises: mixing THF and an argon atmo 
sphere to form a first solution, cooling said first solution to a 
temperature of at least -75° C., preferably -78°C., mixing 
said first solution with LiAlH4 to form a second solution, 
stirring said second solution at a temperature of at least-75° 
C., preferably -78°C., for at least 30 minutes, preferably at 
least 45 minutes and more preferably 60 minutes, raising the 
temperature of said second solution to at least 20° C. over a 
time period of at least six hours, preferably at least seven 
hours and more preferably eight hours, mixing said second 
solution with aqueous NaSO at a temperature of 0° C. to 
form a first salt, mixing said first salt with ether to form a third 
Solution, filtering said third solution using a means for filter 
ing, mixing said third solution with a brine solution to form a 
fourth solution, combining said fourth solution with NaSO, 
separating said fourth solution from said Na2SO, reducing 
the Volume of said fourth Solution using a means for reducing 
said Volume, and recovering said mixture of compounds. In 
further embodiments, said means for reducing Volume is a 
vacuum system. In still further embodiments, said mixture of 
compounds comprises: 
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In additional embodiments, the overall percent yield of said 
mixture of compounds is at least 70% and preferably 72% or 
O. 
In some embodiments, the invention further comprises: 
mixing dioxane to form a first solution, mixing said first 
solution with HCl to form a second solution, stirring said 
second solution for at least 5 minutes, preferably 10 minutes, 
mixing said second solution with NaCNBH to form a third 
solution, refluxing said third solution for at least three hours, 
preferably at least four hours and more preferably five hours, 
cooling said third solution to a temperature of at least 20°C., 
mixing said third solution with diethyl ether and NaOH to 
form a fourth Solution, mixing said fourth Solution with a 
brine solution to form a fifth solution, separating said fifth 
solution from said NaSO, reducing the volume of said fifth 
Solution using a means for reducing said Volume, and recov 
ering said compound. In further embodiments, said means for 
reducing Volume is a vacuum system. In still further embodi 
ments, said compound is: 
In additional embodiments, the overall yield of said com 
pound is at least 60%, preferably at least 65% and more 
preferably 66% or more. In some embodiments, the invention 
relates to a method for synthesizing a compound comprising: 
mixing CHCl to form a first Solution, reducing the tempera 
ture of said first solution to 0°C., mixing said first solution 
with triethylamine and ethyl chloroformate to form a second 
Solution, stirring said second Solution at a temperature of 0° 
C. for at least 30 minutes, preferably 60 minutes, mixing said 
second solution with saturated aqueous NHCl to form a third 
Solution, mixing said third solution with CH2Cl to form a 













tion to form a fifth solution, mixing said fifth solution with 
NaSO, separating said fifth solution from said NaSO, 
reducing the Volume of said fifth solution using a means for 
reducing said Volume, and recovering said compound. In 
further embodiments, said means for reducing Volume is a 
vacuum system. In still further embodiments, said compound 
1S 
In additional embodiments, the overall yield of said com 
pound is at least 85%, preferably at least 89% or more. 
In some embodiments, the invention relates to a method for 
synthesizing a compound comprising: mixing CHCl to 
form a first solution, reducing the temperature of said first 
solution to 0°C., mixing said first solution with methylbro 
mide to form a second solution, stirring said second Solution 
at a temperature of 0°C. for at least 30 minutes, preferably 60 
minutes.<reducing the Volume of said fifth solution using a 
means for reducing said Volume, and recovering said com 
pound. In further embodiments, said means for reducing Vol 
ume is a vacuum system. In still further embodiments, said 
compound is: 
MeO 
In some embodiments, the invention further comprises: mix 
ing acetone and H2O to form a first solution, mixing said first 
solution with 2.2-bromo-3,5-dimethylhydantoin over a 
period of at least 3 minutes to form a second solution, cover 
ing said second solution using a means for covering, stirring 
said second solution for at least 10 hours, preferably at least 
11 hours and more preferably 12 hours, mixing said second 
solution with saturated NHCl to form a third solution, mix 
ing said third solution with water to form a fourth solution, 
mixing said fourth solution with ethyl acetate to form a fifth 
Solution, mixing said fifth solution with a brine solution to 
form a sixth solution, mixing said sixth solution with 
Na2SO, separating said sixth solution from said Na2SO4. 
reducing the Volume of said sixth solution using a means for 
reducing said Volume, and recovering said compound. In 
further embodiments, said means for reducing Volume is a 
vacuum system. In still further embodiments, said means for 
covering comprises an aluminum foil sheet. In additional 
embodiments, said compound is: 
  
  







In some embodiments, the overall yield of said compound is 
at least 95%, preferably 97% or more. 
In some embodiments, the invention further comprises: 
mixing toluene to form a first Solution, mixing said first 
solution with KOH to form a second solution, heating said 
second solution at a temperature of at least 70° C., preferably 
at least 75° C. and more preferably 80°C., for a time period of 
at least 2 hours, preferably 3 hours, reducing the temperature 
of said second Solution, mixing said second solution with 
water to form a third solution, mixing said third solution with 
ethyl acetate to form a fourth Solution, mixing said fourth 
solution with a brine solution to form a fifth solution, mixing 
said fifth solution with NaSO, separating said fifth solution 
from said NaSO, reducing the volume of said fifth solution 
using a means for reducing said Volume, recovering a crude 
extract comprising said compound, and purifying said crude 
extract. In further embodiments, said means for reducing 






In additional embodiments, the overall yield of said com 
pound is at least 90%, preferably at least 95% or more. 
In some embodiments, the invention relates to a method for 
synthesizing a compound comprising: mixing diphenyl dis 
ulfide and ethanol to form a first Solution, mixing said first 
solution with NaBH over a time period of at least 3 minutes, 
preferably 5 minutes, to form a second solution, stirring said 
second solution for at least 10 minutes, preferably 15 min 
utes, mixing said second solution and ethanol to form a third 
Solution, stirring said third solutionata temperature of at least 
20°C. for a time period of at least 1 hour, preferably 2 hours, 
mixing said third solution with water to form a fourth solu 
tion, mixing said fourth solution with CHCl to form a fifth 
Solution, mixing said fifth solution with a brine solution to 
form a sixth solution, mixing said sixth solution with 
Na2SO, separating said sixth solution from said Na2SO4. 
reducing the Volume of said sixth solution using a means for 
reducing said Volume, and recovering said compound. In 
further embodiments, said means for reducing Volume is a 















In additional embodiments, the overall yield of said com 
pound is at least 95%, preferably at least 97% and more 
preferably 99%. In some embodiments, the invention further 
comprises: mixing hexafluoroisopropanol to form a first solu 
tion, mixing said first Solution with hydrogen peroxide to 
form a second solution, stirring said second solution for a 
time period of at least 10 minutes, preferably 15 minutes, 
mixing said second solution with water to form a third solu 
tion, mixing said third solution with Saturated aqueous 
NaSO to form a fourth solution, mixing said fourth solution 
with CHCl to form a fifth solution, mixing said fifth solution 
with a brine solution to form a sixth solution, mixing said 
sixth solution with Na2SO, separating said sixth solution 
from said NaSO4, reducing the Volume of said sixth solution 
using a means for reducing said Volume, and recovering said 
compound. In further embodiments, said means for reducing 




In additional embodiments, the overall yield of said com 
pound is at least 80%, preferably at least 90%, and more 
preferably 93% or more. 
In some embodiments, the invention further comprises: 
mixing THF to form a first Solution, mixing said first Solution 
with LiAlH4 to form a second solution, stirring said second 
solutionata temperature of at least 20°C. for a time period of 
at least 4 hours, preferably at least 5 hours and more prefer 
ably 6 hours, reducing the temperature of said second solution 
to 0°C., mixing said second solution with Saturated aqueous 
NaSO to form a third solution, filtering said third solution 
with Celite, mixing said third solution with diethyl ether to 
form a fourth solution, mixing said fourth solution with 
NaSO, separating said fourth solution from said NaSO, 
reducing the Volume of said fourth Solution using a means for 
reducing said Volume, and recovering said compound. In 
further embodiments, said means for reducing Volume is a 
vacuum system. In still further embodiments, said compound 
1S 
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MeO 
In additional embodiments, the overall yield of said com 
pound is at least 80%, preferably at least 85% and more 
preferably 87% or more. In some embodiments, the invention 
further comprises: mixing chloroform to form a first solution, 
mixing said first solution with boron tribromide to form a 
second solution, stirring said second solutionata temperature 
of at least 20° C. for a time period of at least 15 minutes, 
preferably 20 minutes, mixing said second solution with 
NH-OH at a temperature of 0° C. to form a third solution, 
mixing said third solution with a mixture of CH2Cl and 
ethanol to form a fourth solution, mixing said fourth Solution 
with a brine solution to form a fifth solution, mixing said fifth 
solution with NaSO, separating said fifth solution from said 
Na2SO, reducing the Volume of said fifth solution using a 
means for reducing said Volume to produce an extract, mixing 
said extract with a composition comprising SiO, CHCl and 
ethanol, and recovering said compound. In further embodi 
ments, said means for reducing Volume is a vacuum system. 
In still further embodiments, said compound is: 
In additional embodiments, the overall yield of said com 
pound is at least 80%, preferably at least 85% and more 
preferably 86% or more. 
In some embodiments, the invention further comprises: 
mixing HCl and dioxane to form a first solution, refluxing 
said first solution to produce a first compound, mixing said 
first compound with a composition comprising MeNH2, 
THF, NaBH(OAc)3 and AcOHata temperature of at least 50° 
C., preferably 60° C., to produce a second compound, and 
mixing said second compound with L-Selectride under con 
ditions such that a third compound is produced. In further 














In still further embodiments, said second compound is: 
MeO 
MeO 
In some embodiments, the overall yield of said first com 
pound is at least 85% or more. In further embodiments, the 
overall yield of said second compound is at least 65% or 
more. In still further embodiments, the overall yield of said 
third compound is at least 55% or more. 
In one embodiment, the invention relates to improved 
methods for the synthesis of galanthamine, derivatives, salts 
and intermediates thereof. Galanthamine ((4aS,6R,8aS)-5.6, 
9,10,11,12-hexahydro-3-methoxy-11-methyl-4aH-1 ben 
Zofuro3a,3,2-ef-2-benzazepin-6-ol; C7HHNO; 
MW-287), an amaryllidaceae alkaloid. In one embodiment, 
the compound is contemplated for early treatment of Alzhe 
imer's disease. As noted above, in one embodiment, the 
present invention contemplates that the early synthesis steps 
for morphine and galanthamine are shared (e.g. up to the 
formation of the cross-conjugated 2.5-cyclohexadienone). As 
noted above, the synthesis can thereafter go in the direction of 
morphine (the steps for which have been described above) or 
galanthamine, intermediates, derivatives and salts thereof 
(the steps for which are described below). For example, in 
some embodiments where the synthesis is directed towards 
galanthamine, the present invention further comprises: treat 
ing the cross-conjugated 2.5-cyclohexadienone with acid 
under conditions to cause acid catalyzed hydrolysis of said 
cross-conjugated 2.5-cyclohexadienone so as to forman alde 
hyde-lactol, said aldehyde lactol comprisinga acyl (carbonyl) 
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wherein R is an alkyl, aryl or heteroaryl group or the like or 
a protecting group but not H. R. is an alkyl, aryl or heteroaryl 
group or the like or a protecting group but not H. In still 
further embodiments, said aldehyde-lactol compound is: 
wherein R is an alkyl, aryl or heteroaryl group or the like or 
a protecting group. In some embodiments, the invention fur 
ther comprises: treating said aldehyde-lactol under condi 
tions such that said acyl (carbonyl) group is converted to an 
amine by reductive amination so as to form (t) narwedine 
(including but not limited to an N-alkyl, aryl, heteroaryl, allyl, 
cycopropyl carbinol, or n-propargyl derivative thereof). 
In some embodiments, the invention further comprises: 
wherein (t) narwedine is formed sequentially in the same 
reaction after the formation of a first intermediate, followed 
by a second intermediate. In some embodiments, the inven 
tion further comprises: wherein a narwedine derivative is 
formed sequentially in the same reaction after the formation 
of a first intermediate, followed by a second intermediate. In 
Some embodiments, the invention further comprises wherein 
said first intermediate is an amino-lactol (including but not 
limited to an N-alkyl, aryl, heteroaryl, allyl, cycopropyl 
carbinol, or n-propargyl derivative thereof). In still further 
embodiments, said compound is: 
RO 
% 
wherein R is an alkyl, aryl or heteroaryl group or the like or 
a protecting group; R is an alkyl, aryl or heteroaryl group or 
the like (i.e. other groups such as alkanediyl, alkynyl, arene 
diyl, aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alk 
enyl, alkenediyl, alkynediyl, acyl, alkylidene, methyl, allyl, 
cyclopropyl, carbinol, n-propargyl, non-carbon group, or a 
Substituted version of any of these groups) or a protecting 
group or H. 
In some embodiments, the invention further comprises 
wherein said second intermediate is a carbinolamine ether (a 
“hemiaminal') (including but not limited to an N-alkyl, aryl, 
heteroaryl, allyl, cycopropyl carbinol, or n-propargyl deriva 













wherein R is an alkyl, alkanediyl, alkynyl, aryl, arenediyl. 
aralkyl, heteroaryl, heteroarenediyl, heteroaralkyl, or a Sub 
stituted version of any of these groups or a protecting group, 
or H; and R is an alkyl, aryl or heteroaryl group or the like 
(i.e. other groups such as alkanediyl, alkynyl, arenediyl. 
aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alkenyl, 
alkenediyl, alkynediyl, acyl, alkylidene, methyl, allyl, cyclo 
propyl, carbinol, n-propargyl, non-carbon group, or a Substi 
tuted version of any of these groups) or a protecting group or 
H. 






In some embodiments, said narwedine derivative has the 
Structure: 
wherein R is an alkyl, alkanediyl, alkynyl, aryl, arenediyl. 
aralkyl, heteroaryl, heteroarenediyl, heteroaralkyl, or a Sub 
stituted version of any of these groups or a protecting group, 
or H; and R is an alkyl, aryl or heteroaryl group or the like 
(i.e. other groups such as alkanediyl, alkynyl, arenediyl. 
aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alkenyl, 
alkenediyl, alkynediyl, acyl, alkylidene, methyl, allyl, cyclo 
propyl, carbinol, n-propargyl, non-carbon group, or a Substi 
tuted version of any of these groups) or a protecting group or 
H. 
In some embodiments, the invention further comprises: 
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tive with a reducing agent. Some generic embodiments are 
shown in FIG. 7A. Some specific non-limiting examples of 
contemplated derivatives are shown in FIG. 7B. Some spe 
cific non-limiting examples of contemplated derivatives are 
shown in FIG. 7C. In some embodiments, said galanthamine 
derivative has the structure: 
5 
wherein R is an alkyl, alkanediyl, alkynyl, aryl, arenediyl. 
aralkyl, heteroaryl, heteroarenediyl, heteroaralkyl, or a Sub 
stituted version of any of these groups or a protecting group, 
or H; and R is an alkyl, aryl or heteroaryl group or the like 
(i.e. other groups such as alkanediyl, alkynyl, arenediyl. 
aralkyl, heteroarenediyl, heteroaralkyl, heteroaryl, alkenyl, 
alkenediyl, alkynediyl, acyl, alkylidene, methyl, allyl, cyclo 
propyl, carbinol, n-propargyl, non-carbon group, or a Substi 
tuted version of any of these groups) or a protecting group or 
H. 
In some embodiments, said a galanthamine derivative is 
N-(14-methylallyl)norgalanthamine. In some embodiments, 
said a galanthamine derivative is N-(14-methylallyl)norgal 
anthamine has the structure: 
In some embodiments, said agalanthamine derivative is N-al 
lylnorgalanthamine. In some embodiments, said a galan 















In some embodiments, said a galanthamine derivative is Nor 
galanthamine. In some embodiments, said a galanthamine 
derivative is Norgalanthamine has the structure: 
In some embodiments, the invention further comprises: 
resolving said (t) narwedine into (-)-narwedine in the pres 
ence of galanthamine. In still further embodiments, said 
resolving is in the presence of 1% (+)-galanthamine. In still 
further embodiments, further comprising resolving said (t) 
narwedine into (-)-narwedine in the presence of galan 
thamine with a reducing agent. While it is not intended that 
the present invention be limited by the nature of the reducing 
agent, in a preferred embodiment, said reducing agent is 
L-Selectride. Reduction of (-)-narwedine with L-Selectride 
provides (-)-galanthamine (99%). 
As noted above, the methods permit the further efficient 
synthesis of galanthamine derivatives, such as N-alkyl galan 
thamine derivatives e.g. N-allylnorgalanthamine, N-(14-me 
thylallyl)norgalanthamine, some specific non-limiting 
examples of contemplated derivatives are shown in the struc 
tures in FIG. 10, which are more potent cholinesterase 
inhibitors than galanthamine. In this regard, the above-de 
scribed steps can be modified to create these derivatives. 
Moreover, the present invention contemplates treating and/or 
preventing disease with galanthamine (and derivatives 
thereof) synthesized according to the above scheme and for 
mulated as pharmaceutical formulations. 
BRIEF DESCRIPTION OF THE DRAWINGS 
For a more complete understanding of the features and 
advantages of the present invention, reference is now made to 
the detailed description of the invention along with the 
accompanying figures. 
FIG. 1 shows a biosynthetic pathway for the synthesis of 
morphine and codeine. 
FIG. 2 shows embodiments of the present invention, as 
well as the atomic numbering scheme for morphine. 
FIGS. 3A and B show embodiments of the present inven 
tion for synthesizing a cross-conjugated compound useful in 
the synthesis of both morphine and galanthamine (as well as 
derivatives of both). FIG. 3A provides the general overall 
scheme, while FIG. 3B provides specific (non-limiting) 
examples. 
FIGS. 4A and B show embodiments of the present inven 
tion whereby a cross-conjugated compound is modified in a 
series of steps (and alternative pathways) to create a carbam 
ate and tertiary amine derivatives useful for the synthesis of 
morphine and derivatives thereof. FIG. 4A provides the gen 
eral overall scheme, while FIG. 4B provides specific (non 
limiting) examples. 
FIGS. 5A and B show embodiments of the present inven 
tion whereby a carbamate derivative is modified in a series of 
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compounds (e.g. codeine). FIG. 5A provides the general 
overall scheme, while FIG. 5B provides specific (non-limit 
ing) examples. 
FIG. 6 shows the atomic numbering scheme for galan 
thamine and the structural similarity of narwedine. 
FIGS. 7A and B show embodiments of the present inven 
tion whereby a cross-conjugated compound is modified in a 
series of steps so as to synthesis narwedine and galanthamine. 
FIG. 7A provides the general overall scheme, while FIG. 7B 
provides specific (non-limiting) examples. Compounds 2, 14. 
24, 25 and 26 are racemates, but the structures are drawn in 
FIG. 7B (for clarity) as a single enantiomer with their con 
figuration corresponding to that of (-)-galanthamine. FIG.7C 
provides specific (non-limiting) examples. FIG. 7C provides 
an alternative synthetic route for the production of narwedine 
and galanthamine. Compounds 2, 14, 24, and 27 are race 
mates, but the structures are drawn in FIG. 7C (for clarity) as 
a single enantiomer with their configuration corresponding to 
that of (-)-galanthamine. 
FIGS. 8A and B show embodiments of the present inven 
tion whereby certain R, derivatives of the cross-conjugate can 
be made. FIG. 8A provides the general overall scheme, while 
FIG. 8B provides specific (non-limiting) examples. 
FIGS. 9A and B show embodiments of the present inven 
tion wherein a novel epoxide is used to make useful down 
stream derivatives (including but not limited to 7-B substi 
tuted 7,8-dihydro derivatives). FIG. 9A provides the general 
overall scheme, while FIG.9B provides specific (non-limit 
ing) examples. 
FIG. 10 shows the structure of some specific non-limiting 
examples of galanthamine derivatives, such as N-alkyl gal 
anthamine derivatives e.g. N-allylnorgalanthamine, N-(14 
methylallyl)norgalanthamine, the structures for which are 
shown in FIG. 10. 
DEFINITIONS 
To facilitate the understanding of this invention, a number 
of terms are defined below. Terms defined herein have mean 
ings as commonly understood by a person of ordinary skill in 
the areas relevant to the present invention. Terms such as “a”, 
“an and “the are not intended to refer to only a singular 
entity, but include the general class of which a specific 
example may be used for illustration. The terminology herein 
is used to describe specific embodiments of the invention, but 
their usage does not delimit the invention, except as outlined 
in the claims. 
As used herein, "cross-conjugated refers to a compound 
where in there are (at least) two double bonds that are conju 
gated to a “central double bond in such a way that the It 
electronic system forms a bifurcation. 
As used herein, “morphine” refers to a compound repre 













where R is H. It is not intended that the invention be limited to 
any particular derivative, analog or isomer of morphine or salt 
thereof. Examples of derivatives of morphine include but are 
in no way limited to morphine, morphine acetate, morphine 
citrate, morphine bitartrate, morphine Stearate, morphine 
phthalate, morphine hydrobromide, morphine 
hydrobromide.2H2O, morphine hydrochloride, morphine 
hydrochloride.3HO, morphine hydriodide.2H2O, morphine 
lactate, morphine monohydrate, morphine meconate.5H2O. 
morphine mucate, morphine nitrate, morphine 
phosphate.0.5H2O, morphine phosphate.7H2O, morphine 
salicylate, morphine phenylpropionate, morphine methylio 
dide, morphine isobutyrate, morphine hypophosphite, mor 
phine sulfate.5H2O, morphine tannate, morphine 
tartrate.3H2O, morphine Valerate, morphine methylbromide, 
morphine methylsulfonate, morphine-N-oxide, morphine-N- 
oxide quinate, dihydromorphine and pseudomorphine. It is 
not intended that the present invention be limited by the type 
of chemical substituent or substituents that is or are coordi 
nated to morphine. Examples of chemical Substituents 
include but are in no way limited to hydrogen, methyl, ethyl, 
formyl, acetyl, phenyl, chloride, bromide, hydroxyl, meth 
oxyl, ethoxyl, methylthiol, ethylthiol, propionyl, carboxyl, 
methoxy carbonyl, ethoxycarbonyl, methylthiocarbonyl, eth 
ylthiocarbonyl, butylthiocarbonyl, dimethylcarbamyl, dieth 
ylcarbamyl, N-piperidinylcarbonyl, N-methyl-N'-piperazi 
nylcarbonyl, 2-(dimethylamino)ethylcarboxy, 
N-morpholinylcarbonyl, 2-(dimethylamino)ethylcarbamyl, 
1-piperidinylcarbonyl, methylsulfonyl, ethylsulfonyl, phe 
nylsulfonyl, 2-piperidinylethyl, 2-morpholinylethyl, 2-(dim 
ethylamino)ethyl, 2-(diethylamino)ethyl, butylthiol, dim 
ethylamino, diethylamino, piperidinyl, pyrrolidinyl, 
imidazolyl pyrazolyl. N-methylpiperazinyl and 2-(dimethy 
lamino)ethylamino. 
As used herein, “codeine' refers to a compound repre 
sented by the following chemical structure: 
where R is CH, also referred to as a methyl (Me) substituent. 
It is not intended that the invention be limited to any particular 
derivative, analog or isomer of codeine or salt thereof. 
Examples of derivatives of codeine include but are in no way 
limited to codeine, codeine acetate, codeine citrate, codeine 
bitartrate, codeine Stearate, codeinephthalate, codeine hydro 
bromide, codeine hydrobromide2HO, codeine hydrochlo 
ride, codeine hydrochloride.3H2O, codeine 
hydriodide.2H2O, codeine lactate, codeine monohydrate, 
codeine meconate.5H2O, codeine mucate, codeine nitrate, 
codeine phosphate.0.5H2O, codeine phosphate.7H2O, 
codeine Salicylate, codeine phenylpropionate, codeine meth 
yliodide, codeine isobutyrate, codeine hypophosphite, 
codeine sulfate.5H2O, codeine tannate, codeine 
tartrate.3H2O, codeine Valerate, codeine methylbromide, 
codeine methylsulfonate, codeine-N-oxide, codeine-N-oxide 
quinate and pseudocodeine. It is not intended that the present 
invention be limited by the type of chemical substituent or 
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Substituents that is or are coordinated to codeine. Examples of 
chemical substituents include but are in no way limited to 
hydrogen, methyl, ethyl, formyl, acetyl, phenyl, chloride, 
bromide, hydroxyl, methoxyl, ethoxyl, methylthiol, eth 
ylthiol, propionyl, carboxyl, methoxy carbonyl, ethoxycarbo 
nyl, methylthiocarbonyl, ethylthiocarbonyl, butylthiocarbo 




methylsulfonyl, ethylsulfonyl, phenylsulfonyl, 2-piperidinyl 
ethyl, 2-morpholinylethyl, 2-(dimethylamino)ethyl, 2-(di 
ethylamino)ethyl, butylthiol, dimethylamino, diethylamino, 
piperidinyl, pyrrolidinyl, imidazolyl pyrazolyl. N-meth 
ylpiperazinyl and 2-(dimethylamino)ethylamino. 
As used herein, "galanthamine' refers to a compound rep 
resented by the following chemical structure: 
5 
It is not intended that the invention be limited to any particular 
derivative, analog or isomer of galanthamine or salt thereof. 
Examples of derivatives of galanthamine include but are in no 
way limited to galanthamine, galanthamine acetate, galan 
thamine citrate, galanthamine bitartrate, galanthamine Stear 
ate, galanthamine phthalate, galanthamine hydrobromide, 
galanthamine hydrobromide.2H2O, galanthamine hydro 
chloride, galanthamine hydrochloride.3H2O, galanthamine 
hydriodide.2H2O, galanthamine lactate, galanthamine mono 
hydrate, galanthamine meconate.5H2O. galanthamine 
mucate, galanthamine nitrate, galanthamine 
phosphate.0.5H2O. galanthamine phosphate.7H2O, galan 
thamine salicylate, galanthamine phenylpropionate, galan 
thamine methyliodide, galanthamine isobutyrate, galan 
thamine hypophosphite, galanthamine Sulfate.5H2O. 
galanthamine tannate, galanthamine tartrate.3H2O, galan 
thamine Valerate, galanthamine methylbromide, galan 
thamine methylsulfonate, galanthamine-N-oxide, galan 
thamine-N-oxide quinate and pseudogalanthamine. It is not 
intended that the present invention be limited by the type of 
chemical substituent or substituents that is or are coordinated 
to galanthamine. Examples of chemical Substituents include 
but are in no way limited to hydrogen, methyl, ethyl, formyl. 
acetyl, phenyl, chloride, bromide, hydroxyl, methoxyl, 
ethoxyl, methylthiol, ethylthiol, propionyl, carboxyl, meth 
oxy carbonyl, ethoxycarbonyl, methylthiocarbonyl, ethylth 
iocarbonyl, butylthiocarbonyl, dimethylcarbamyl, diethyl 
carbamyl, N-piperidinylcarbonyl, N-methyl-N'- 
piperazinylcarbonyl, 2-(dimethylamino)ethylcarboxy, 
N-morpholinylcarbonyl, 2-(dimethylamino)ethylcarbamyl. 
1-piperidinylcarbonyl, methylsulfonyl, ethylsulfonyl, phe 
nylsulfonyl, 2-piperidinylethyl, 2-morpholinylethyl, 2-(dim 
ethylamino)ethyl 2-(diethylamino)ethyl, butylthiol, dim 
ethylamino, diethylamino, piperidinyl, pyrrolidinyl, 














As used herein, “narwedine' refers to a compound repre 
sented by the following chemical structure: 
It is not intended that the invention be limited to any particular 
derivative, analog or isomer of narwedine or salt thereof. 
Examples of derivatives of narwedine include but are in no 
way limited to narwedine, narwedine acetate, narwedine cit 
rate, narwedine bitartrate, narwedine Stearate, narwedine 
phthalate, narwedine hydrobromide, narwedine 
hydrobromide.2H2O, narwedine hydrochloride, narwedine 
hydrochloride.3H2O, narwedine hydriodide.2H2O, narwed 
ine lactate, narwedine monohydrate, narwedine 
meconate.5H2O, narwedine mucate, narwedine nitrate, nar 
wedine phosphate.0.5H2O, narwedine phosphate.7H2O, nar 
wedine salicylate, narwedine phenylpropionate, narwedine 
methyliodide, narwedine isobutyrate, narwedine hypophos 
phite, narwedine sulfate.5H2O, narwedine tannate, narwed 
ine tartrate.3H2O, narwedine Valerate, narwedine methylbro 
mide, narwedine methylsulfonate, narwedine-N-oxide, 
narwedine-N-oxide quinate and pseudonarwedine. It is not 
intended that the present invention be limited by the type of 
chemical substituent or substituents that is or are coordinated 
to narwedine. Examples of chemical substituents include but 
are in no way limited to hydrogen, methyl, ethyl, formyl. 
acetyl, phenyl, chloride, bromide, hydroxyl, methoxyl, 
ethoxyl, methylthiol, ethylthiol, propionyl, carboxyl, meth 
oxy carbonyl, ethoxycarbonyl, methylthiocarbonyl, ethylth 
iocarbonyl, butylthiocarbonyl, dimethylcarbamyl, diethyl 
carbamyl, N-piperidinylcarbonyl, N-methyl-N'- 
piperazinylcarbonyl, 2-(dimethylamino)ethylcarboxy, 
N-morpholinylcarbonyl, 2-(dimethylamino)ethylcarbamyl, 
1-piperidinylcarbonyl, methylsulfonyl, ethylsulfonyl, phe 
nylsulfonyl, 2-piperidinylethyl, 2-morpholinylethyl, 2-(dim 
ethylamino)ethyl 2-(diethylamino)ethyl, butylthiol, dim 
ethylamino, diethylamino, piperidinyl, pyrrolidinyl, 
imidazolyl pyrazolyl. N-methylpiperazinyl and 2-(dimethy 
lamino)ethylamino. 
A “Suzuki reaction” refers to a chemical reaction between 
an aryl- or vinyl-boronic acid with an aryl- or vinylhalide that 
is catalyzed via a palladium complex as provided for in U.S. 
Pat. No. 6,136,157 to Lindeberg et al., incorporated herein by 
reference. While not limiting the scope of the present inven 
tion, the reaction is used to synthesize poly-olefins, styrenes, 
Substituted biphenyl complexes and incorporate alkylhalides 
including but in no way limited to alkyl bromides. 
A “Henry aldol' reaction, also referred to as a “nitroaldol 
reaction, is a reaction carried out between an aldehyde and 
nitromethane as provided for in U.S. Pat. No. 7.312,191 to 
Rose et al., incorporated herein by reference. The reaction 
results in the synthesis of a B-hydroxy nitrosylated com 
pound, also referred to as a nitroethylene compound. 
A "Grignard reagent” refers to chemical reagents which 
are prepared by the reaction of magnesium metal with an 
organic halide. Grignard reagents refer to any of a class of 
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reagents with the general formula RMgX, in which R is an 
organic radical, including but not limited to where R is an 
alkyl or aryl, and X is a halogen. Grignard reagents are used 
as a source of nucleophillic carbon. It is known that the 
preparation of Grignard reagents are often quite difficult. 
Formation of these reagents is inhibited by the presence of 
water and alcohols, ethers and halides and by impurities on 
the Surface of the magnesium turnings. While not limiting the 
Scope of the present invention, the reagent is commonly used 
but not limited to reacting with acyl, epoxide, alcohols, het 
erocyclic, carboxylic acids, esters, ethers, and and other elec 
trophilic atoms. 
As used herein, "alkaloid” refers to a member of the class 
of naturally occurring chemical compounds containing basic 
nitrogen atoms. Alkaloids are produced by a large variety of 
organisms, with many exhibiting pharmacological effects. 
While not limiting the scope of the present invention, alka 
loids are often formulated as salts to enhance their solubility 
under physiological conditions. Examples of alkaloid salt 
counterions include the appropriate counterion derived from 
but in no way limited to mineral acids such as hydrochloric 
acid and Sulfuric acid as well as organic acid counter ions 
including but not limited to tartaric acid and maleic acid. 
“Epimers' refer to diastereomers that differ in configura 
tion of only one stereogenic center. Diastereomers are a class 
of stereoisomers that are non-Superposable, non-mirror 
images of one another, unlike enantiomers that are non-Su 
perposable mirror images of one another. 
The term "salts', as used herein, refers to any salt that 
complexes with identified compounds contained herein while 
retaining a desired function, e.g., biological activity. 
Examples of Such salts include, but are not limited to, acid 
addition salts formed with inorganic acids (e.g. hydrochloric 
acid, hydrobromic acid, Sulfuric acid, phosphoric acid, nitric 
acid, and the like), and salts formed with organic acids Such 
as, but not limited to, acetic acid, oxalic acid, tartaric acid, 
Succinic acid, malic acid, fumaric acid, maleic acid, ascorbic 
acid, benzoic acid, tannic acid, pamoic acid, alginic acid, 
polyglutamic, acid, naphthalene Sulfonic acid, naphthalene 
disulfonic acid, and polygalacturonic acid. 
As used herein, “hydrogen' means —H; “hydroxy' means 
—OH: “oxo” means —O; “halo' means independently —F. 
—Cl, Br or —I: "amino” means —NH. (see below for 
definitions of groups containing the term amino, e.g., alky 
lamino); “hydroxyamino” means —NHOH: “nitro” means 
—NO; imino means —NH (see below for definitions of 
groups containing the term imino, e.g., alkylamino); "cyano' 
means—CN; “azido” means—N; “mercapto' means—SH: 
“thio’ means —S; “sulfonamido” means —NHS(O) (see 
below for definitions of groups containing the term Sulfona 
mido, e.g., alkylsulfonamido); "sulfonyl' means —S(O) - 
(see below for definitions of groups containing the term Sul 
fonyl, e.g., alkylsulfonyl); and “silyl means —SiH (See 
below for definitions of group(s) containing the term silyl, 
e.g., alkylsilyl). 
For the groups below, the following parenthetical sub 
scripts further define the groups as follows: “(Cn) defines the 
exact number (n) of carbon atoms in the group: "(Cisn)” 
defines the maximum number (n) of carbon atoms that can be 
in the group; (Cn-n') defines both the minimum (n) and 
maximum number (n') of carbon atoms in the group. For 
example, "alkoxyc-lo” designates those alkoxy groups 
having from 1 to 10 carbon atoms (e.g., 1,2,3,4,5,6,7,8,9, 
or 10, or any range derivable therein (e.g., 3-10 carbon 














groups having from 2 to 10 carbonatoms (e.g., 2, 3, 4, 5, 6, 7, 
8, 9, or 10, or any range derivable therein (e.g., 3-10 carbon 
atoms)). 
The term “alkyl” when used without the “substituted” 
modifier refers to a non-aromatic monovalent group with a 
saturated carbon atom as the point of attachment, a linear or 
branched, cyclo, cyclic or acyclic structure, no carbon-carbon 
double or triple bonds, and no atoms other than carbon and 
hydrogen. The groups, —CH (Me), —CH2CH (Et), 
—CHCHCH (n-Pr), —CH(CH), (iso-Pr), —CH(CH), 
(cyclopropyl), —CH2CHCH-CH (n-Bu), —CH(CH) 
CHCH (sec-butyl), —CHCH(CH), (iso-butyl), 
—C(CH) (tert-butyl), —CHC(CH) (neo-pentyl), 
cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexylmethyl 
are non-limiting examples of alkyl groups. The term 'substi 
tuted alkyl refers to a non-aromatic monovalent group with 
a Saturated carbon atom as the point of attachment, a linear or 
branched, cyclo, cyclic or acyclic structure, no carbon-carbon 
double or triple bonds, and at least one atom independently 
selected from the group consisting of N, O, F, Cl, Br, I, Si, P. 
and S. The following groups are non-limiting examples of 
substituted alkyl groups: —CHOH, -CHCl, —CHBr, 
—CH2SH, CF, -CHCN, -CHC(O)H, -CHC(O) 
OH, -CHC(O)CCH, -CHC(O)NH, -CHC(O) 
NHCH, -CHC(O)CH, CHOCH, CHOCHCF, 
—CHOC(O)CH, -CH-NH. —CH-NHCH, CHN 
(CH), —CHCHCl, —CH2CH2OH. —CHCF, 
- CHCHOC(O)CH, -CHCH-NHCOC(CH), and 
—CHSiCCH). 
The term "alkanediyl when used without the “substituted 
modifier refers to a non-aromatic divalent group, wherein the 
alkanediyl group is attached with two O-bonds, with one or 
two saturated carbon atom(s) as the point(s) of attachment, a 
linear or branched, cyclo, cyclic or acyclic structure, no car 
bon-carbon double or triple bonds, and no atoms other than 
carbon and hydrogen. The groups, —CH2— (methylene), 
—CH2CH2—, —CHC(CH3)2CH2—, —CH2CH2CH2—, 
and 
are non-limiting examples of alkanediyl groups. The term 
“substituted alkanediyl refers to a non-aromatic monovalent 
group, wherein the alkynediyl group is attached with two 
O-bonds, with one or two Saturated carbon atom(s) as the 
point(s) of attachment, a linear or branched, cyclo, cyclic or 
acyclic structure, no carbon-carbon double or triple bonds, 
and at least one atom independently selected from the group 
consisting of N, O, F, Cl, Br, I, Si, P, and S. The following 
groups are non-limiting examples of Substituted alkanediyl 
groups: —CH(F)— —CF, , —CH(Cl)—, —CH(OH)—, 
—CH(OCH)—, and —CHCH(Cl)—. 
The term “alkenyl' when used without the “substituted 
modifier refers to a monovalent group with a nonaromatic 
carbon atom as the point of attachment, a linear or branched, 
cyclo, cyclic or acyclic structure, at least one nonaromatic 
carbon-carbon double bond, no carbon-carbon triple bonds, 
and no atoms other than carbon and hydrogen. Non-limiting 
examples of alkenyl groups include: —CH=CH (vinyl). 
CH=CHCH, CH=CHCHCH, CH-CH=CH, 
(allyl), —CH-CH=CHCH, and -CH=CH-CHs. The 
term “substituted alkenyl refers to a monovalent group with 
a nonaromatic carbonatom as the point of attachment, at least 
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one nonaromatic carbon-carbon double bond, no carbon-car 
bontriple bonds, a linear or branched, cyclo, cyclic or acyclic 
structure, and at least one atom independently selected from 
the group consisting of N, O, F, Cl, Br, I, Si, P. and S. The 
groups, -CH=CHF, -CH=CHC1 and -CH=CHBr, are 
non-limiting examples of Substituted alkenyl groups. 
The term “alkenediyl when used without the “substituted 
modifier refers to a non-aromatic divalent group, wherein the 
alkenediyl group is attached with two O-bonds, with two 
carbon atoms as points of attachment, a linear or branched, 
cyclo, cyclic or acyclic structure, at least one nonaromatic 
carbon-carbon double bond, no carbon-carbon triple bonds, 
and no atoms other than carbon and hydrogen. The groups, 
-CH=CH-, -CH=C(CH)CH -, -CH=CHCH , 
and 
are non-limiting examples of alkenediyl groups. The term 
“substituted alkenediyl refers to a non-aromatic divalent 
group, wherein the alkenediyl group is attached with two 
O-bonds, with two carbon atoms as points of attachment, a 
linear or branched, cyclo, cyclic or acyclic structure, at least 
one nonaromatic carbon-carbon double bond, no carbon-car 
bontriple bonds, and at least one atom independently selected 
from the group consisting of N, O, F, Cl, Br, I, Si, P. and S. The 
following groups are non-limiting examples of Substituted 
alkenediyl groups: —CF=CH , —C(OH)—CH , and 
—CH-CH=C(C1)-. 
The term “alkynyl' when used without the “substituted 
modifier refers to a monovalent group with a nonaromatic 
carbon atom as the point of attachment, a linear or branched, 
cyclo, cyclic or acyclic structure, at least one carbon-carbon 
triple bond, and no atoms other than carbon and hydrogen. 
The groups, —C=CH, —C=CCH. —C=CCHs and 
—CH2C=CCH are non-limiting examples of alkynyl 
groups. The term “substituted alkynyl refers to a monovalent 
group with a nonaromatic carbonatom as the point of attach 
ment and at least one carbon-carbon triple bond, a linear or 
branched, cyclo, cyclic or acyclic structure, and at least one 
atom independently selected from the group consisting of N. 
O. F. Cl, Br, I, Si, P, and S. The group, —C=CSi (CH), is a 
non-limiting example of a Substituted alkynyl group. 
The term “alkynediyl when used without the “substi 
tuted” modifier refers to a non-aromatic divalent group, 
wherein the alkynediyl group is attached with two O-bonds, 
with two carbon atoms as points of attachment, a linear or 
branched, cyclo, cyclic or acyclic structure, at least one car 
bon-carbon triple bond, and no atoms other than carbon and 
hydrogen. The groups. -C=C-, -C=CCH , and 
—C=CCH(CH)—are non-limiting examples of alkynediyl 
groups. The term “substituted alkynediyl refers to a non 
aromatic divalent group, wherein the alkynediyl group is 
attached with two O-bonds, with two carbon atoms as points 
of attachment, a linear or branched, cyclo, cyclic or acyclic 
structure, at least one carbon-carbon triple bond, and at least 
one atom independently selected from the group consisting of 
N, O, F, Cl, Br, I, Si, P, and S. The groups-C=CCFH and 
—C=CHCH(Cl)—are non-limiting examples of substituted 
alkynediyl groups. 
The term “aryl' when used without the “substituted” modi 
fier refers to a monovalent group with an aromatic carbon 













part of a six-membered aromatic ring structure wherein the 
ring atoms are all carbon, and wherein the monovalent group 
consists of no atoms other than carbon and hydrogen. Non 
limiting examples of aryl groups include phenyl (Ph), meth 
ylphenyl, (dimethyl)phenyl, —CHCH-CH (ethylphenyl), 
—CHCHCH-CH (propylphenyl), —CHCH(CH), 
—CHCH(CH), —CH (CH)CHCH (methylethylphe 
nyl), —CH-CH=CH (vinylphenyl), —CH-CH= 
CHCH. —CHCCH, —CHC=CCH, naphthyl, and the 
monovalent group derived from biphenyl. The term “substi 
tuted aryl” refers to a monovalent group with an aromatic 
carbon atom as the point of attachment, said carbon atom 
forming part of a six-membered aromatic ring structure 
wherein the ring atoms are all carbon, and wherein the 
monovalent group further has at least one atom independently 
selected from the group consisting of N, O, F, Cl, Br, I, Si, P. 
and S. Non-limiting examples of Substituted aryl groups 
include the groups: —CHF, —CHCl, —CHBr, 
—CHI, —CHOH, -CHOCH, —CHOCH2CH, 
—CHOC(O)CH, —CH-NH2, —CHNHCH 
—CHN(CH), —CHCH-OH, -CHCHOC(O)CH, 
—CHCH-NH. —CHCF. —CHCN, —CHCHO, 
—CHCHO, —CHC(O)CH, —CHC(O)CHs. 
—CHCO2H. —CHCOCH, —CHCONH2, 
—CHCONHCH, and —CHCON(CH). 
The term “arenediyl when used without the “substituted 
modifier refers to a divalent group, wherein the arenediyl 
group is attached with two O-bonds, with two aromatic car 
bonatoms as points of attachment, said carbonatoms forming 
part of one or more six-membered aromatic ring structure(s) 
wherein the ring atoms are all carbon, and wherein the 
monovalent group consists of no atoms other than carbon and 





The term “substituted arenediyl refers to a divalent group, 
wherein the arenediyl group is attached with two O-bonds, 
with two aromatic carbon atoms as points of attachment, said 
carbon atoms forming part of one or more six-membered 
aromatic rings structure(s), wherein the ring atoms are all 
carbon, and wherein the divalent group further has at least one 
atom independently selected from the group consisting of N. 
O, F, Cl, Br, I, Si, P, and S. 
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The term “aralkyl when used without the “substituted 
modifier refers to the monovalent group -alkanediyl-aryl, in 
which the terms alkanediyl and aryl are each used in a manner 
consistent with the definitions provided above. Non-limiting 
examples of aralkyls are: phenylmethyl (benzyl, Bn), 1-phe 
nyl-ethyl 2-phenyl-ethyl, indenyl and 2,3-dihydro-indenyl, 
provided that indenyl and 2,3-dihydro-indenyl are only 
examples of aralkyl in So far as the point of attachment in each 
case is one of the saturated carbon atoms. When the term 
“aralkyl is used with the “substituted modifier, either one or 
both the alkanediyl and the aryl is substituted. Non-limiting 
examples of substituted aralkyls are: (3-chlorophenyl)-me 
thyl, 2-oxo-2-phenyl-ethyl(phenylcarbonylmethyl), 
2-chloro-2-phenyl-ethyl, chromanyl where the point of 
attachment is one of the Saturated carbon atoms, and tetrahy 
droquinolinyl where the point of attachment is one of the 
saturated atoms. 
The term "heteroaryl' when used without the “substituted 
modifier refers to a monovalent group with an aromatic car 
bon atom or nitrogen atom as the point of attachment, said 
carbon atom or nitrogen atom forming part of an aromatic 
ring structure wherein at least one of the ring atoms is nitro 
gen, oxygen or Sulfur, and wherein the monovalent group 
consists of no atoms other than carbon, hydrogen, aromatic 
nitrogen, aromatic oxygen and aromatic Sulfur. Non-limiting 
examples of aryl groups include acridinyl, furanyl, imida 
Zoimidazolyl, imidazopyrazolyl, imidazopyridinyl, imida 
Zopyrimidinyl, indolyl, indazolinyl, methylpyridyl, oxazolyl, 
phenylimidazolyl pyridyl, pyrrolyl pyrimidyl, pyrazinyl, 
quinolyl, quinazolyl, quinoxalinyl, tetrahydroquinolinyl, 
thienyl, triazinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyr 
rolopyrazinyl, pyrrolotriazinyl, pyrroloimidazolyl, chrome 
nyl (where the point of attachment is one of the aromatic 
atoms), and chromanyl (where the point of attachment is one 
of the aromatic atoms). The term “substituted heteroaryl 
refers to a monovalent group with an aromatic carbonatom or 
nitrogenatom as the point of attachment, said carbon atom or 
nitrogen atom forming part of an aromatic ring structure 
wherein at least one of the ring atoms is nitrogen, oxygen or 
Sulfur, and wherein the monovalent group further has at least 
one atom independently selected from the group consisting of 
non-aromatic nitrogen, non-aromatic oxygen, non aromatic 
sulfur F, Cl, Br, I, Si, and P. 
The term "heteroarenediyl when used without the “sub 
stituted modifier refers to a divalent group, wherein the 
heteroarenediyl group is attached with two O-bonds, with an 
aromatic carbon atom or nitrogenatom as the point of attach 
ment, said carbon atom or nitrogen atom two aromatic atoms 
as points of attachment, said carbon atoms forming part of 
one or more six-membered aromatic ring structure(s) wherein 
the ring atoms are all carbon, and wherein the monovalent 
group consists of no atoms other than carbon and hydrogen. 
Non-limiting examples of heteroarenediyl groups include: 
N 














The term “substituted heteroarenediyl refers to a divalent 
group, wherein the heteroarenediyl group is attached with 
two O-bonds, with two aromatic carbon atoms as points of 
attachment, said carbon atoms forming part of one or more 
six-membered aromatic rings structure(s), wherein the ring 
atoms are all carbon, and wherein the divalent group further 
has at least one atom independently selected from the group 
consisting of N, O, F, Cl, Br, I, Si, P, and S. 
The term "heteroaralkyl when used without the “substi 
tuted modifier refers to the monovalent group -alkanediyl 
heteroaryl, in which the terms alkanediyl and heteroaryl are 
each used in a manner consistent with the definitions provided 
above. Non-limiting examples of aralkyls are: pyridylmethyl, 
and thienylmethyl. When the term "heteroaralkyl is used 
with the “substituted” modifier, either one or both the 
alkanediyl and the heteroaryl is substituted. 
The term “acyl when used without the “substituted 
modifier refers to a monovalent group with a carbon atom of 
a carbonyl group as the point of attachment, further having a 
linear or branched, cyclo, cyclic or acyclic structure, further 
having no additional atoms that are not carbon or hydrogen, 
beyond the oxygen atom of the carbonyl group. The groups, 
—COCH (CH), and —C(O)CH2CHs are non-limiting 
examples of acyl groups. The term “acyl therefore encom 
passes, but is not limited to groups sometimes referred to as 
“alkyl carbonyl' and “aryl carbonyl groups. The term “sub 
stituted acyl refers to a monovalent group with a carbonatom 
of a carbonyl group as the point of attachment, further having 
a linear or branched, cyclo, cyclic or acyclic structure, further 
having at least one atom, in addition to the oxygen of the 
carbonyl group, independently selected from the group con 
sisting of N, O, F, Cl, Br, I, Si, P. and S. The groups, —C(O) 
CHCF. —COH (carboxyl), —COCH (methylcarboxyl), 
—COCHCH —COCH2CHCH —COCHs. 
—COCH(CH), —COCH(CH), —C(O)NH (carbam 
oyl), C(O)NHCH, C(O)NHCHCH, CONHCH 
(CH), CONHCH(CH), —CON(CH), 
—CONHCHCF. —CO pyridyl, -CO-imidazoyl, and 
—C(O)N are non-limiting examples of Substituted acyl 
groups. The term 'substituted acyl encompasses, but is not 
limited to, "heteroaryl carbonyl groups. 
The term “alkylidene' when used without the “substituted 
modifier refers to the divalent group —CRR', wherein the 
alkylidene group is attached with one O-bond and one 
JL-bond, in which RandR' are independently hydrogen, alkyl, 
or R and R' are taken together to represent alkanediyl. Non 
limiting examples of alkylidene groups include: =CH2. 
—CH(CHCH), and —C(CH). The term “substituted 
alkylidene’ refers to the group —CRR', wherein the alky 
lidene group is attached with one O-bond and one U-bond, in 
which R and R are independently hydrogen, alkyl, substi 
tuted alkyl, or R and R' are taken together to represent a 
substituted alkanediyl, provided that either one of RandR is 
a substituted alkyl or RandR are taken together to represent 
a substituted alkanediyl. 
The term “alkoxy' when used without the “substituted 
modifier refers to the group —OR, in which R is an alkyl, as 
that term is defined above. Non-limiting examples of alkoxy 
groups include: —OCH —OCHCH —OCH2CHCH 
—OCH(CH), —OCH(CH), —O-cyclopentyl, and —O- 
cyclohexyl. The term “substituted alkoxy' refers to the group 
—OR, in which R is a substituted alkyl, as that term is defined 
above. For example, —OCHCF is a substituted alkoxy 
group. 
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Similarly, the terms “alkenyloxy”, “alkynyloxy”, “ary 
loxy”, “aralkoxy”, “heteroaryloxy”, “heteroaralkoxy” and 
“acyloxy”, when used without the “substituted modifier, 
refers to groups, defined as —OR, in which R is alkenyl, 
alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and acyl, 
respectively, as those terms are defined above. When any of 
the terms alkenyloxy, alkynyloxy, aryloxy, aralkyloxy and 
acyloxy is modified by “substituted, it refers to the group 
—OR, in which R is substituted alkenyl, alkynyl, aryl, 
aralkyl, heteroaryl, heteroaralkyl and acyl, respectively. 
The term “alkylamino' when used without the “substi 
tuted modifier refers to the group - NHR, in which R is an 
alkyl, as that term is defined above. Non-limiting examples of 
alkylamino groups include: —NHCH, -NHCHCH 
—NHCHCHCH, -NHCH(CH), -NHCH(CH), 
—NHCHCHCHCH NHCH(CH)CHCH 
—NHCH-CH(CH), NHC(CH), NH-cyclopentyl, 
and —NH-cyclohexyl. The term “substituted alkylamino” 
refers to the group —NHR, in which R is a substituted alkyl, 
as that term is defined above. For example, NHCHCF is 
a Substituted alkylamino group. 
The term “dialkylamino” when used without the “substi 
tuted modifier refers to the group —NRR", in which Rand R' 
can be the same or different alkyl groups, or R and R' can be 
taken together to represent an alkanediyl having two or more 
saturated carbon atoms, at least two of which are attached to 
the nitrogen atom. Non-limiting examples of dialkylamino 
groups include: —NHC(CH), —N(CH)CHCH 
—N(CHCH), N-pyrrolidinyl, and N-piperidinyl. The term 
“substituted dialkylamino” refers to the group —NRR", in 
which Rand R' can be the same or different substituted alkyl 
groups, one of R or R' is an alkyl and the other is a substituted 
alkyl, or R and R' can be taken together to represent a substi 
tuted alkanediyl with two or more Saturated carbon atoms, at 
least two of which are attached to the nitrogen atom. 
The terms “alkoxyamino”, “alkenylamino”, “alkyny 
lamino”, “arylamino”, “aralkylamino”, “heteroarylamino', 
"heteroaralkylamino', and “alkylsulfonylamino” when used 
without the “substituted modifier, refers to groups, defined 
as NHR, in which R is alkoxy, alkenyl, alkynyl, aryl, 
aralkyl, heteroaryl, heteroaralkyl and alkylsulfonyl, respec 
tively, as those terms are defined above. A non-limiting 
example of an arylamino group is —NHCHs. When any of 
the terms alkoxyamino, alkenylamino, alkynylamino, ary 
lamino, aralkylamino, heteroarylamino, heteroaralkylamino 
and alkylsulfonylamino is modified by “substituted, it refers 
to the group —NHR, in which R is substituted alkoxy, alk 
enyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and 
alkylsulfonyl, respectively. 
The term "amido” (acylamino), when used without the 
“substituted modifier, refers to the group —NHR, in which 
R is acyl, as that term is defined above. A non-limiting 
example of an acylamino group is NHC(O)CH. When the 
term amido is used with the “substituted” modifier, it refers to 
groups, defined as —NHR, in which R is substituted acyl, as 
that term is defined above. The groups —NHC(O)OCH and 
—NHC(O)NHCH are non-limiting examples of substituted 
amido groups. 
The term “alkylimino” when used without the “substi 
tuted modifier refers to the group —NR, wherein the alky 
limino group is attached with one O-bond and one U-bond, in 
which R is an alkyl, as that term is defined above. Non 
limiting examples of alkylimino groups include: =NCH, 
—NCHCH and —N-cyclohexyl. The term “substituted 
alkylimino” refers to the group —NR, wherein the alkylimino 














is a substituted alkyl, as that term is defined above. For 
example, —NCHCF is a substituted alkylimino group. 
Similarly, the terms “alkenylimino”, “alkynylimino', 
“arylimino”, “aralkylimino”, “heteroarylimino”, “het 
eroaralkylimino” and “acylimino”, when used without the 
“substituted modifier, refers to groups, defined as —NR, 
wherein the alkylimino group is attached with one O-bond 
and one U-bond, in which R is alkenyl, alkynyl, aryl, aralkyl, 
heteroaryl, heteroaralkyl and acyl, respectively, as those 
terms are defined above. When any of the terms alkenylimino, 
alkynylimino, arylimino, aralkylimino and acylimino is 
modified by “substituted, it refers to the group —NR, 
wherein the alkylimino group is attached with one O-bond 
and one U-bond, in which R is substituted alkenyl, alkynyl, 
aryl, aralkyl, heteroaryl, heteroaralkyl and acyl, respectively. 
The term “alkylthio' when used without the “substituted” 
modifier refers to the group —SR, in which R is an alkyl, as 
that term is defined above. Non-limiting examples of alky 
lthio groups include: —SCH, —SCHCH 
—SCHCHCH. —SCH(CH), —SCH(CH), —S-cy 
clopentyl, and —S-cyclohexyl. The term “substituted alky 
lthio’ refers to the group —SR, in which R is a substituted 
alkyl, as that termis defined above. For example, SCHCF 
is a Substituted alkylthio group. 
Similarly, the terms “alkenylthio”, “alkynylthio', 
“arylthio”, “aralkylthio”, “heteroarylthio”, “heteroaralky 
lthio', and “acylthio', when used without the “substituted 
modifier, refers to groups, defined as —SR, in which R is 
alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and 
acyl, respectively, as those terms are defined above. When any 
of the terms alkenylthio, alkynylthio, arylthio, aralkylthio. 
heteroarylthio, heteroaralkylthio, and acylthio is modified by 
“substituted, it refers to the group —SR, in which R is 
Substituted alkenyl, alkynyl, aryl, aralkyl, heteroaryl, het 
eroaralkyl and acyl, respectively. 
The term “thioacyl when used without the “substituted 
modifier refers to a monovalent group with a carbon atom of 
a thiocarbonyl group as the point of attachment, further hav 
ing a linear or branched, cyclo, cyclic or acyclic structure, 
further having no additional atoms that are not carbon or 
hydrogen, beyond the Sulfur atom of the carbonyl group. The 
groups, —CHS, —C(S)CH, —C(S)CHCH. —C(S) 
CHCHCH, C(S)CH(CH), C(S)CH(CH), C(S) 
CHs —C(S)CHCH. —C(S)CHCHCH. —C(S)CH 
(CH), and —C(S)CH2CHs are non-limiting examples of 
thioacyl groups. The term “thioacyl therefore encompasses, 
but is not limited to, groups sometimes referred to as “alkyl 
thiocarbonyl and “arylthiocarbonyl groups. The term “sub 
stituted thioacyl refers to a radical with a carbon atom as the 
point of attachment, the carbon atom being part of a thiocar 
bonyl group, further having a linear or branched, cyclo, cyclic 
or acyclic structure, further having at least one atom, in addi 
tion to the Sulfur atom of the carbonyl group, independently 
selected from the group consisting of N, O, F, Cl, Br, I, Si, P. 
and S. The groups, —C(S)CHCF. —C(S)OH, - C(S) 
OCH, C(S)OCHCH, C(S)OCHCHCH, C(S) 
OCHs, C(S)OCH(CH), C(S)OCH(CH), C(S) 
NH, and C(S)NHCH, are non-limiting examples of 
substituted thioacyl groups. The term “substituted thioacyl 
encompasses, but is not limited to, "heteroaryl thiocarbonyl 
groups. 
The term “alkylsulfonyl when used without the “substi 
tuted” modifier refers to the group—S(O),R, in which Risan 
alkyl, as that term is defined above. Non-limiting examples of 
alkylsulfonyl groups include: —S(O)CH, -S(O) 
CHCH. —S(O)CHCHCH. —S(O)CH(CH), 
—S(O)CH(CH2), —S(O)-cyclopentyl, and —S(O)-cy 
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clohexyl. The term “substituted alkylsulfonyl refers to the 
group—S(O),R, in which Risa substituted alkyl, as that term 
is defined above. For example. —S(O)CHCF is a substi 
tuted alkylsulfonyl group. 
Similarly, the terms “alkenylsulfonyl', 'alkynylsulfonyl', 
“arylsulfonyl”, “aralkylsulfonyl', "heteroarylsulfonyl', and 
"heteroaralkylsulfonyl' when used without the “substituted 
modifier, refers to groups, defined as —S(O).R. in which Ris 
alkenyl, alkynyl, aryl, aralkyl, heteroaryl, and heteroaralkyl, 
respectively, as those terms are defined above. When any of 
the terms alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, 
aralkylsulfonyl, heteroarylsulfonyl, and heteroaralkyl 
sulfonyl is modified by “substituted, it refers to the group 
—S(O),R, in which R is substituted alkenyl, alkynyl, aryl, 
aralkyl, heteroaryland heteroaralkyl, respectively. 
The term “alkylammonium' when used without the “sub 
stituted modifier refers to a group, defined as NHR'. 
NHRR", or NRRR", in which R, R' and R" are the 
same or different alkyl groups, or any combination of two of 
R. R' and R" can be taken together to represent an alkanediyl. 
Non-limiting examples of alkylammonium cation groups 
include: —NH2(CH), NH(CHCH)+, —NH 
(CHCHCH)+, NH(CH), -NH(CHCH), -NH 
(CH2CHCH), —N(CH), —N(CH)(CHCH).", 
—N(CH)(CHCH)", —NHC(CH), —NH(cyclopen 
tyl)", and —NH-(cyclohexyl)". The term “substituted alky 
lammonium” refers - NHR'. - NHRR", or NRRR", in 
which at least one of R. RandR" is a substituted alkyl or two 
of R. RandR" can be taken together to represent a substituted 
alkanediyl. When more than one of R, R and R" is a substi 
tuted alkyl, they can be the same of different. Any of R. Rand 
R" that are not either substituted alkyl or substituted 
alkanediyl, can be either alkyl, either the same or different, or 
can be taken together to represent a alkanediyl with two or 
more carbon atoms, at least two of which are attached to the 
nitrogen atom shown in the formula. 
The term “alkylsulfonium' when used without the “substi 
tuted modifier refers to the group —SRR", in which R and 
R" can be the same or different alkyl groups, or R and R' can 
be taken together to represent an alkanediyl. Non-limiting 
examples of alkylsulfonium groups include: —SH(CH), 
—SH(CHCH)", -SH(CHCHCH)", S(CH).", 
—S(CH2CH), —S(CH2CH2CH). —SH(cyclopen 
tyl)", and —SH(cyclohexyl)". The term “substituted alkyl 
sulfonium” refers to the group —SRR", in which R and R' 
can be the same or different substituted alkyl groups, one of R 
or R' is an alkyl and the other is a substituted alkyl, or Rand 
R" can be taken together to represent a substituted alkanediyl. 
For example, SH(CHCF.)" is a substituted alkylsulfo 
nium group. 
The term “alkylsilyl” when used without the “substituted” 
modifier refers to a monovalent group, defined as —SiHR, 
–SiHRR', or -SiRR'R", in which R, R and R" can be the 
same or different alkyl groups, or any combination of two of 
R. R' and R" can be taken together to represent an alkanediyl. 
The groups, SiHCH. —SiH(CH), —Si(CH) and—Si 
(CH3)2C(CH), are non-limiting examples of unsubstituted 
alkylsilyl groups. The term “substituted alkylsilyl refers 
—SiHR, SiHRR', or - SiRRR", in which at least one of 
R, R and R" is a substituted alkyl or two of R. R' and R" can 
be taken together to represent a substituted alkanediyl. When 
more than one of R, R and R" is a substituted alkyl, they can 
be the same of different. Any of R. RandR" that are not either 
substituted alkyl or substituted alkanediyl, can be either alkyl, 
either the same or different, or can be taken together to rep 
resenta alkanediyl with two or more Saturated carbon atoms, 














In addition, atoms making up the compounds of the present 
invention are intended to include all isotopic forms of such 
atoms. Isotopes, as used herein, include those atoms having 
the same atomic number but different mass numbers. By way 
of general example and without limitation, isotopes of hydro 
gen include tritium and deuterium, and isotopes of carbon 
include 'Cand C. Similarly, it is contemplated that one or 
more carbon atom(s) of a compound of the present invention 
may be replaced by a silicon atom(s). Furthermore, it is con 
templated that one or more oxygenatom(s) of a compound of 
the present invention may be replaced by a Sulfur or selenium 
atom(s). 
A compound having a formula that is represented with a 
dashed bond is intended to include the formulae optionally 
having Zero, one or more double bonds. Thus, for example, 
the structure 
includes the structures 
OOOO. O. 
As will be understood by a person of skill in the art, no one 
Such ring atom forms part of more than one double bond. 
Any undefined Valency on an atom of a structure shown in 
this application implicitly represents a hydrogen atom 
bonded to the atom. 
A ring structure shown with an unconnected “R” group, 
indicates that any implicit hydrogenatom on that ring can be 
replaced with that R group. In the case of a divalent R group 
(e.g., oxo, imino, thio, alkylidene, etc.), any pair of implicit 
hydrogen atoms attached to one atom of that ring can be 
replaced by that R group. This concept is as exemplified 
below: 
represents 
As used herein, a "chiral auxiliary” refers to a removable 
chiral group that is capable of influencing the Stereoselectiv 
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ity of a reaction. Persons of skill in the art are familiar with 
Such compounds, and many are commercially available. 
The term “protecting group, as that term is used in the 
specification and/or claims, is used in the conventional 
chemical sense as a group, which reversibly renders unreac 
tive a functional group under certain conditions of a desired 
reaction and is understood not to be H. After the desired 
reaction, protecting groups may be removed to deprotect the 
protected functional group. All protecting groups should be 
removable (and hence, labile) under conditions which do not 
degrade a Substantial proportion of the molecules being Syn 
thesized. In contrast to a protecting group, a “capping group' 
permanently binds to a segment of a molecule to prevent any 
further chemical transformation of that segment. It should be 
noted that the functionality protected by the protecting group 
may or may not be a part of what is referred to as the protect 
ing group. 
Protecting groups include but are not limited to: Alcohol 
protecting groups: Acetoxy group, 3-Methoxyethoxymethyl 
ether (MEM), methoxymethyl ether (MOM), p-methoxyben 
Zyl ether (PMB), methylthiomethyl ether, pivaloyl (Piv), tet 
rahydropyran (THP), silyl ethers (including but not limited to 
trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), and 
triisopropylsilyl (TIPS) ethers), methyl ethers, and ethoxy 
ethyl ethers (EE). Amine protecting groups: carbobenzyloxy 
(Cbz) group, p-methoxybenzyl carbonyl (Moz or MeOZ) 
group, tert-butyloxycarbonyl (BOC) group, 9-fluorenylm 
ethyloxycarbonyl (FMOC) group, benzyl (Bn) group, 
p-methoxybenzyl (PMB), dimethoxybenzyl (DMPM), 
p-methoxyphenyl (PMP) group, tosyl (Ts) group, and other 
sulfonamides (Nosyl & Nps) groups. Carbonyl protecting 
groups: acetals, ketals, acylals, and dithianes. Carboxylic 
acid protecting groups: alkyl esters, aryl esters, silyl esters. 
Protection of terminal alkynes protected as propargyl alco 
hols in the Favorskii reaction. 
The term “leaving group, as that term is used in the speci 
fication and/or claims, is an atom or group (charged or 
uncharged) that becomes detached from an atom in what is 
considered to be the residual or main part of the substrate in a 
specified reaction. 
Leaving groups include, but are not limited to: NH 
(amine), CHO (methoxy), HO (hydroxyl), CHCOO 
(carboxylate), HO (water), F, Cl, Br, IT, N (azide), 
SCNT (thiocyanate), NO (nitro), and protecting groups. 
The use of the word “a” or “an when used in conjunction 
with the term “comprising in the claims and/or the specifi 
cation may mean "one.” but it is also consistent with the 
meaning of “one or more.” “at least one.” and “one or more 
than one.” 
Throughout this application, the term “about is used to 
indicate that a value includes the inherent variation of error 
for the device, the method being employed to determine the 
value, or the variation that exists among the study subjects. 
The terms “comprise.” “have and “include” are open 
ended linking verbs. Any forms or tenses of one or more of 
these verbs, such as "comprises.” “comprising.” “has.” “hav 
ing,” “includes” and “including.” are also open-ended. For 
example, any method that “comprises.” “has or “includes’ 
one or more steps is not limited to possessing only those one 
or more steps and also covers other unlisted steps. 
The term “effective,” as that term is used in the specifica 
tion and/or claims, means adequate to accomplish a desired, 
expected, or intended result. 
The term “hydrate' when used as a modifier to a compound 
means that the compound has less than one (e.g., hemihy 













drate) water molecules associated with each compound mol 
ecule. Such as in Solid forms of the compound. 
As used herein, the term “ICso refers to an inhibitory dose 
which is 50% of the maximum response obtained. 
An "isomer of a first compound is a separate compound in 
which each molecule contains the same constituent atoms as 
the first compound, but where the configuration of those 
atoms in three dimensions differs. 
As used herein, the term “patient’ or “subject” refers to a 
living mammalian organism, such as a human, monkey, cow, 
sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic 
species thereof. In certain embodiments, the patientor Subject 
is a primate. Non-limiting examples of human Subjects are 
adults, juveniles, infants and fetuses. 
"Pharmaceutically acceptable” means that which is useful 
in preparing a pharmaceutical composition that is generally 
safe, non-toxic and neither biologically nor otherwise unde 
sirable and includes that which is acceptable for veterinary 
use as well as human pharmaceutical use. 
"Pharmaceutically acceptable salts' means salts of com 
pounds of the present invention which are pharmaceutically 
acceptable, as defined above, and which possess the desired 
pharmacological activity. Such salts include acid addition 
salts formed with inorganic acids Such as hydrochloric acid, 
hydrobromic acid, Sulfuric acid, nitric acid, phosphoric acid, 
and the like; or with organic acids such as 1.2-ethanedisul 
fonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalene 
Sulfonic acid, 3-phenylpropionic acid, 4,4'-methylenebis(3- 
hydroxy-2-ene-1-carboxylic acid), 4-methylbicyclo[2.2.2 
oct-2-ene-1-carboxylic acid, acetic acid, aliphatic mono- and 
dicarboxylic acids, aliphatic Sulfuric acids, aromatic Sulfuric 
acids, benzenesulfonic acid, benzoic acid, camphorsulfonic 
acid, carbonic acid, cinnamic acid, citric acid, cyclopen 
tanepropionic acid, ethanesulfonic acid, fumaric acid, gluco 
heptonic acid, gluconic acid, glutamic acid, glycolic acid, 
heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic 
acid, laurylsulfuric acid, maleic acid, malic acid, malonic 
acid, mandelic acid, methanesulfonic acid, muconic acid, 
o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chloroben 
Zenesulfonic acid, phenyl-substituted alkanoic acids, propi 
onic acid, p-toluenesulfonic acid, pyruvic acid, Salicylic acid, 
Stearic acid, Succinic acid, tartaric acid, tertiarybutylacetic 
acid, trimethylacetic acid, and the like. Pharmaceutically 
acceptable salts also include base addition salts which may be 
formed when acidic protons present are capable of reacting 
with inorganic or organic bases. Acceptable inorganic bases 
include Sodium hydroxide, Sodium carbonate, potassium 
hydroxide, aluminum hydroxide and calcium hydroxide. 
Acceptable organic bases include ethanolamine, diethanola 
mine, triethanolamine, tromethamine, N-methylglucamine 
and the like. It should be recognized that the particular anion 
or cation forming a part of any salt of this invention is not 
critical, so long as the salt, as a whole, is pharmacologically 
acceptable. Additional examples of pharmaceutically accept 
able salts and their methods of preparation and use are pre 
sented in Handbook of Pharmaceutical Salts. Properties, and 
Use (P. H. Stahl & C. G. Wermuth eds., Verlag Helvetica 
Chimica Acta, 2002), 
As used herein, "predominantly one enantiomer means 
that a compound contains at least about 85% of one enanti 
omer, or more preferably at least about 90% of one enanti 
omer, or even more preferably at least about 95% of one 
enantiomer, or most preferably at least about 99% of one 
enantiomer. Similarly, the phrase “substantially free from 
other optical isomers' means that the composition contains at 
most about 15% of another enantiomer or diastereomer, more 
preferably at most about 10% of another enantiomer or dias 
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tereomer, even more preferably at most about 5% of another 
enantiomer or diastereomer, and most preferably at most 
about 1% of another enantiomer or diastereomer. 
“Prevention' or “preventing includes: (1) inhibiting the 
onset of a disease in a Subject or patient which may be at risk 
and/or predisposed to the disease but does not yet experience 
or display any or all of the pathology or symptomatology of 
the disease, and/or (2) slowing the onset of the pathology or 
symptomatology of a disease in a Subject or patient which 
may be at risk and/or predisposed to the disease but does not 
yet experience or display any or all of the pathology or symp 
tomatology of the disease. 
“Prodrug' means a compound that is convertible in vivo 
metabolically into an inhibitor according to the present inven 
tion. The prodrug itselfmay or may not also have activity with 
respect to a given target protein. For example, a compound 
comprising a hydroxy group may be administered as an ester 
that is converted by hydrolysis in vivo to the hydroxy com 
pound. Suitable esters that may be converted in vivo into 
hydroxy compounds include acetates, citrates, lactates, phos 
phates, tartrates, malonates, oxalates, salicylates, propi 
onates. Succinates, fumarates, maleates, methylene-bis-B-hy 
droxynaphthoate, gentisates, isethionates, di-p- 
toluoyltartrates, methane-Sulfonates, ethanesulfonates, 
benzenesulfonates, p-toluenesulfonates, cyclohexyl-Sulfa 
mates, quinates, esters of amino acids, and the like. Similarly, 
a compound comprising an amine group may be administered 
as an amide that is converted by hydrolysis in vivo to the 
amine compound. 
The term “saturated when referring to an atom means that 
the atom is connected to other atoms only by means of single 
bonds. 
A “stereoisomer' or “optical isomer' is an isomer of a 
given compound in which the same atoms are bonded to the 
same other atoms, but where the configuration of those atoms 
in three dimensions differs. "Enantiomers' are stereoisomers 
of a given compound that are mirror images of each other, like 
left and right hands. “Diastereomers' are stereoisomers of a 
given compound that are not enantiomers. 
Enantiomers are compounds that individually have prop 
erties said to have “optical activity” and consist of chiral 
molecules. If a chiral molecule is dextrorotary, its enantiomer 
will be levorotary, and vice-versa. In fact, the enantiomers 
will rotate polarized light the same number of degrees, but in 
opposite directions. “Dextrorotation' and “levorotation' 
(also spelled laevorotation) refer, respectively, to the proper 
ties of rotating plane polarized light clockwise (for dextroro 
tation) or counterclockwise (for levorotation). A compound 
with dextrorotation is called "dextrorotary, while a com 
pound with levorotation is called “levorotary'. 
A standard measure of the degree to which a compound is 
dextrorotary or levorotary is the quantity called the “specific 
rotation’ “C.”. Dextrorotary compounds have a positive spe 
cific rotation, while levorotary compounds have negative. 
Two enantiomers have equal and opposite specific rotations. 
A dextrorotary compound is prefixed “(+)- or “d-”. Like 
wise, a levorotary compound is often prefixed “(-)- or “l-”. 
These “d-' and “l-prefixes should not be confused with the 
“D- and “L- prefixes based on the actual configuration of 
each enantiomer, with the version synthesized from naturally 
occurring (+)-compound being considered the D-form. A 
mixture of enantiomers of the compounds is prefixed “(+)-”. 
An equal mixture of enantiomers of the compounds is con 
sidered "optically inactive'. 
When used herein, unless otherwise specified, “morphine' 
refers to a mixture of enantiomers of morphine, “(t)-mor 















thamine refers to a mixture of enantiomers of galanthamine, 
“(t) galanthamine, or a single enantiomer, e.g. "(-)-galan 
thamine.” 
Compounds 2, 14, 24, 25 and 26 are racemates, but the 
structures are drawn in FIGS. 7A & B (for clarity) as a single 
enantiomer with their configuration corresponding to that of 
(-)-galanthamine. 
The invention contemplates that for any stereocenter or 
axis of chirality for which stereochemistry has not been 
defined, that stereocenter or axis of chirality can be present in 
its R form, S form, or as a mixture of the R and S forms, 
including racemic and non-racemic mixtures. 
“Substituent convertible to hydrogen in Vivo” means any 
group that is convertible to a hydrogen atom by enzymologi 
cal or chemical means including, but not limited to, hydroly 
sis and hydrogenolysis. Examples include hydrolyzable 
groups, such as acyl groups, groups having an oxycarbonyl 
group, amino acid residues, peptide residues, o-nitrophenyl 
Sulfenyl, trimethylsilyl, tetrahydro-pyranyl, diphenylphos 
phinyl, and the like. Examples of acyl groups include formyl. 
acetyl, trifluoroacetyl, and the like. Examples of groups hav 
ing an oxycarbonyl group include ethoxycarbonyl, tert-bu 
toxycarbonyl ( C(O)CC(CH)), benzyloxycarbonyl, 
p-methoxybenzyloxycarbonyl, vinyloxycarbonyl, B-(p-tolu 
enesulfonyl)ethoxycarbonyl, and the like. 
The present invention contemplates the above-described 
compositions in “therapeutically effective amounts” or 
“pharmaceutically effective amounts”, which means that 
amount which, when administered to a subject or patient for 
treating a disease, is Sufficient to effect Such treatment for the 
disease or to emeliorate one or more symptoms of a disease or 
condition (e.g. emeliorate pain). 
The above definitions supersede any conflicting definition 
in any of the reference that is incorporated by reference 
herein. 
The present invention contemplates, in certain embodi 
ments inhibiting or preventing disease (e.g. treating early 
Alzheimer's with galanthamine). As used herein, the terms 
“prevent and “preventing include the prevention of the 
recurrence, spread or onset of a disease or disorder. It is not 
intended that the present invention be limited to complete 
prevention. In some embodiments, the onset is delayed, or the 
severity of the disease or disorder is reduced. Studies with 
galanthamine have showed mild cognitive and global benefits 
for patients with Alzheimer's disease. 
As used herein, the terms “treat' and “treating are not 
limited to the case where the Subject (e.g. patient) is cured and 
the disease is eradicated. Rather, the present invention also 
contemplates treatment that merely reduces symptoms, 
improves (to some degree) and/or delays disease progression. 
It is not intended that the present invention be limited to 
instances wherein a disease or affliction is cured. It is suffi 
cient that symptoms are reduced. 
“Subject” refers to any mammal, preferably a human 
patient, livestock, or domestic pet. 
In a specific embodiment, the term “pharmaceutically 
acceptable” means approved by a regulatory agency of the 
federal or a state government or listed in the U.S. Pharma 
copeia or other generally recognized pharmacopeia for use in 
animals, and more particularly in humans. The term "carrier 
refers to a diluent, adjuvant, excipient or vehicle with which 
the active compound is administered. Such pharmaceutical 
vehicles can be liquids, such as water and oils, including those 
of petroleum, animal, vegetable or synthetic origin, such as 
peanut oil, soybean oil, mineral oil, Sesame oil and the like. 
The pharmaceutical vehicles can be saline, gum acacia, gela 
tin, starch paste, talc, keratin, colloidal silica, urea, and the 
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like. In addition, auxiliary, stabilizing, thickening, lubricating 
and coloring agents can be used. When administered to a 
Subject, the pharmaceutically acceptable vehicles are prefer 
ably sterile. Water can be the vehicle when the active com 
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istry, Rahman, A, editor. Volume 18, Stereoselective Synthe 
sis (Part K): A Historical Perspective of Morphine Syntheses, 
Hudlicky, T.; Butora, G.; Fearnley, S.P.: Gum, A. G.; Stabile, 
M. R. 1996, 43-154. Elsevier Publishers, New York; The 
pound is administered intravenously. Saline solutions and 5 Alkaloids, Cordell. G. A. and Brossi, A., editors. Volume 45, 
aqueous dextrose and glycerol Solutions can also be 
employed as liquid vehicles, particularly for injectable solu 
tions. Suitable pharmaceutical vehicles also include excipi 
ents such as starch, glucose, lactose, Sucrose, gelatin, malt, 
rice, flour, chalk, silica gel, Sodium Stearate, glycerol 
monostearate, talc, sodium chloride, dried skim milk, glyc 
erol, propylene glycol, water, ethanol and the like. The 
present compositions, if desired, can also contain minor 
amounts of wetting or emulsifying agents, or pH buffering 
agents. 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention relates to methods for the synthesis 
of morphine and derivatives thereof. In preferred embodi 
ments, the invention relates to methods for improving the 
efficiency and overall yield of said morphine and derivatives. 
It is not intended that the present invention be limited to any 
particular chemical, biochemical or biological mechanism or 
theory. 
In preferred embodiments, the invention relates to methods 
and compositions comprising morphine and derivatives 
thereof. Morphine ((5C,6O)-7,8-didehydro-4,5-epoxy-17 
methylmorphinan-3,6-diol; C2HNO; MW-285.4), a 
member of the alkaloid class of compounds, is a highly effec 
tive analgesic used in a myriad of pharmaceutical and bio 
medical applications. While there are numerous reported syn 
thetic strategies for obtaining limited quantities and percent 
yields of morphine alkaloids such as Zezula et al. (2007) 
Synlett, 2863-2867; Omori et al. (2007) Synlett, 2859-2862: 
Uchida et al. (2006) Org. Lett. 8,5311-5313 and Trost et al. 
(2005).J. Am. Chem. Soc. 127, 14785-14803, all of which are 
hereby incorporated by reference, one of the most practical 
synthetic strategies for obtaining opium alkaloids is the Rice 
adaptation of the Grewe strategy as provided for in Rice 
(1980).J. Org. Chem. 45,3135-3137, hereby incorporated by 
reference. While not limiting the scope of the current inven 
tion, the biosynthetic steps utilized by nature for the genera 
tion of morphine alkaloids is well understood. As provided 
for in FIG. 1, (R)-reticuline (1) is converted into salutaridine 
(2) through an enzymatically mediated ortho-para phenolic 
oxidation as provided for in Bartonetal. (1965) Journal of the 
Chemical Society, 2423-2438, incorporated herein by refer 
ence. Salutaridine (2) is Subsequently transformed in vivo 
into codienone 3 (via thebaine), which is reduced to codeine 
(4) and demethylated to give morphine (5). 
The efficient phenolic oxidative pathway undertaken in 
plants to the most effective analgesics in all of medicinal 
practice underscores the need to deduce the enzymatically 
controlled pathway to these agents. However, attempts to 
mimic Such aesthetic chemistry in the laboratory for the prac 
tical production of these important compounds in an efficient 
and economical manner, has not resulted in practical yields of 
(2) or related derivatives. 
While not limiting the scope of the present invention to any 
particular theory, one of the central issues in morphine and 
morphine derivative synthesis is the construction of the cross 
conjugated 2,5-cyclohexadienone chromophore imbedded 
within salutaridine (2) in an effective practical manner. 
Clearly, the published methods have been overwhelmingly 
influenced by the Barton phenolic oxidative biogenetic 












Chapter 2. “The Morphine Alkaloids. Szántay, C.; Dörnyei, 
G.; Blask6, G. 1994, 128-222. Academic Press, NewYork and 
Barton, D. H. R. Kirby, G. W.; Steglich, W.; Thomas, G. M.: 
Battersby, A. R.; Dobson, T.A. and Ramuz, H. (1965) Journal 
of the Chemical Society, 2423-2438, all of which are hereby 
incorporated by reference. While phenolic oxidation provides 
a structurally simplifying and unifying explanation of a large 
number of natural product structures, it has, at an experimen 
tal level, invariably resulted in low yields when applied to the 
in vitro conversion of phenols into cross-conjugated 2,5-cy 
clohexadienones. While intramolecular C-alkylation of phe 
nols to form 2.5-cyclohexadienones has been employed, and 
the applications of this non-oxidative methodology to the 
synthesis of a wide range of both natural and unnatural prod 
ucts, this type of reaction has not been used for the synthesis 
of morphinans. It is known that intramolecular alkylation of 
phenolate anions can result in O-alkylation (remains aro 
matic), versus C-alkylation of the phenolate anion that results 
in either 2,4- or 2.5-conjugated cyclohexadienones. While 
not limiting the present invention to any particular theory or 
mechanism, applying the intramolecular phenol alkylation 
reaction (FIG. 2) to the synthesis of a suitably substituted 
cross-conjugated 2.5-cyclohexadienone would require, in its 
simplest form, the conversion of (6) into (7). The acetal (C. 
carbon atom) in (7) will eventually evolve into the D-ring of 
morphine by a reductive amination reaction. 
In preferred embodiments, the invention relates to 
improved methods for the synthesis of galanthamine and 
intermediates thereof. Galanthamine ((4aS,6R,8aS)-5,6,9. 
10,11,12-hexahydro-3-methoxy-11-methyl-4aH-1 benzo 
furo3a,3,2-ef-2-benzazepin-6-ol; CHNO; 
MW-287), an amaryllidaceae alkaloid, has found extensive 
use in the early treatment of Alzheimer's disease. The com 
pound may be isolated via synthesis or from plants such as the 
Caucasian Snowdrop (Voronov's Snowdrop), Lycoris radiata 
(red spider lily) and Galanthus woronowi (Amaryllidaceae) 
and related species. While not limiting the present invention 
to any particular theory, it is believed that the compound is 
metabolized primarily through the liver. The extraction of 
galanthamine from the bulbs of the aforementioned species 
does not supply Sufficient material for the on-going clinical 
evaluation and treatment of early Alzheimer's patients. Com 
mercially available Supplies of galanthamine are obtained via 
a laborious nine-step synthetic scheme that results in an over 
all yield of only 12.4% as provided for in Kienburg et al. 
(1999) Organic Process Research and Development 3, 425 
431, incorporated herein by reference. These difficulties in 
obtaining Sufficient Supplies of galanthamine underscore the 
need for more efficient synthetic strategies for obtaining the 
compound. 
Pharmaceutical Formulations 
The present compositions can take the form of Solutions, 
Suspensions, emulsion, tablets, pills, pellets, capsules, cap 
Sules containing liquids, powders, Sustained-release formu 
lations, Suppositories, emulsions, aerosols, sprays, Suspen 
sions, or any other form Suitable for use. In one embodiment, 
the pharmaceutically acceptable vehicle is a capsule (see e.g., 
U.S. Pat. No. 5,698,155, hereby incorporated by reference). 
In a preferred embodiment, the active compound and 
optionally another therapeutic or prophylactic agent are for 
mulated in accordance with routine procedures as pharma 
ceutical compositions adapted for intravenous administration 
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to human beings. Typically, the active compounds for intra 
venous administration are solutions in sterile isotonic aque 
ous buffer. Where necessary, the compositions can also 
include a solubilizing agent. Compositions for intravenous 
administration can optionally include a local anesthetic Such 
as lignocaine to ease pain at the site of the injection. Gener 
ally, the ingredients are Supplied either separately or mixed 
together in unit dosage form, for example, as a dry lyophilized 
powder or water free concentrate in a hermetically sealed 
container Such as an ampoule or Sachette indicating the quan 
tity of active agent. Where the active compound is to be 
administered by infusion, it can be dispensed, for example, 
with an infusion bottle containing sterile pharmaceutical 
grade water or saline. Where the active compound is admin 
istered by injection, an ampoule of sterile water for injection 
or saline can be provided so that the ingredients can be mixed 
prior to administration. 
Compositions for oral delivery can be in the form of tablets, 
lozenges, aqueous or oily Suspensions, granules, powders, 
emulsions, capsules, syrups, or elixirs, for example. Orally 
administered compositions can contain one or more optional 
agents, for example, Sweetening agents such as fructose, 
aspartame or saccharin, flavoring agents such as peppermint, 
oil of wintergreen, orcherry; coloring agents; and preserving 
agents, to provide a pharmaceutically palatable preparation. 
Moreover, where in tablet or pill form, the compositions can 
be coated to delay disintegration and absorption in the gas 
trointestinal tract thereby providing a Sustained action overan 
extended period of time. Selectively permeable membranes 
Surrounding an osmotically active driving compound are also 
suitable for an orally administered of the active compound. In 
these later platforms, fluid from the environment surrounding 
the capsule is imbibed by the driving compound, which 
Swells to displace the agent or agent composition through an 
aperture. These delivery platforms can provide an essentially 
Zero order delivery profile as opposed to the spiked profiles of 
immediate release formulations. A time delay material Such 
as glycerol monostearate or glycerol Stearate can also be used. 
Oral compositions can include standard vehicles such as 
mannitol, lactose, starch, magnesium Stearate, sodium sac 
charine, cellulose, magnesium carbonate, and the like. Such 
vehicles are preferably of pharmaceutical grade. 
Further, the effect of the active compound can be delayed 
or prolonged by proper formulation. For example, a slowly 
soluble pellet of the active compound can be prepared and 
incorporated in a tablet or capsule. The technique can be 
improved by making pellets of several different dissolution 
rates and filling capsules with a mixture of the pellets. Tablets 
or capsules can be coated with a film that resists dissolution 
for a predictable period of time. Even the parenteral prepara 
tions can be made long acting, by dissolving or Suspending 
the compound in oily or emulsified vehicles, which allow it to 
disperse only slowly in the serum. 
Compositions for use in accordance with the present inven 
tion can be formulated in conventional manner using one or 
more physiologically acceptable carriers or excipients. 
Thus, the compound and optionally another therapeutic or 
prophylactic agent and their physiologically acceptable salts 
and Solvates can be formulated into pharmaceutical compo 
sitions for administration by inhalation or insufflation (either 
through the mouth or the nose) or oral, parenteral or mucosol 
(such as buccal, vaginal, rectal, Sublingual) administration. In 
Some embodiments, the administration is optical (e.g. eyes 
drops applied directly to the eye). In one embodiment, local or 
systemic parenteral administration is used. 
For oral administration, the compositions can take the form 













means with pharmaceutically acceptable excipients such as 
binding agents (e.g., pregelatinised maize starch, polyvi 
nylpyrrolidone or hydroxypropyl methylcellulose); fillers 
(e.g., lactose, microcrystalline cellulose or calcium hydrogen 
phosphate); lubricants (e.g., magnesium Stearate, talc or 
silica); disintegrants (e.g., potato starch or sodium starch 
glycolate); or wetting agents (e.g., sodium lauryl Sulfate). The 
tablets can be coated by methods well known in the art. Liquid 
preparations for oral administration can take the form of for 
example, Solutions, syrups or Suspensions, or they can be 
presented as a dry product for constitution with water or other 
suitable vehicle before use. Such liquid preparations can be 
prepared by conventional means with pharmaceutically 
acceptable additives such as Suspending agents (e.g., Sorbitol 
syrup, cellulose derivatives or hydrogenated edible fats); 
emulsifying agents (e.g., lecithin or acacia); non-aqueous 
vehicles (e.g., almond oil, oily esters, ethyl alcohol or frac 
tionated vegetable oils); and preservatives (e.g., methyl or 
propyl-p-hydroxybenzoates or Sorbic acid). The preparations 
can also contain buffer salts, flavoring, coloring and Sweet 
ening agents as appropriate. 
Preparations for oral administration can be suitably formu 
lated to give controlled release of the active compound. 
For buccal administration the compositions can take the 
form of tablets or lozenges formulated in conventional man 
. 
For administration by inhalation, the compositions for use 
according to the present invention are conveniently delivered 
in the form of an aerosol spray presentation from pressurized 
packs or a nebulizer, with the use of a Suitable propellant, e.g., 
dichlorodifluoromethane, trichlorofluoromethane, dichlo 
rotetrafluoroethane, carbon dioxide or other suitable gas. In 
the case of a pressurized aerosol the dosage unit can be 
determined by providing a valve to deliver a metered amount. 
Capsules and cartridges of e.g., gelatin for use in an inhaler or 
insufflator can be formulated containing a powder mix of the 
compound and a suitable powder base such as lactose or 
starch. 
The compositions can be formulated for parenteral admin 
istration by injection, e.g., by bolus injection or continuous 
infusion. Formulations for injection can be presented in unit 
dosage form, e.g., in ampoules or in multi-dose containers, 
with an added preservative. The pharmaceutical composi 
tions can take such forms as Suspensions, solutions or emul 
sions in oily oraqueous vehicles, and can contain formulatory 
agents such as Suspending, stabilizing and/or dispersing 
agents. Alternatively, the active ingredient can be in powder 
form for constitution with a suitable vehicle, e.g., sterile 
pyrogen-free water, before use. 
In addition to the formulations described previously, the 
compositions can also be formulated as a depot preparation. 
Such long acting formulations can be administered by 
implantation (for example Subcutaneously or intramuscu 
larly) or by intramuscular injection. Thus, for example, the 
pharmaceutical compositions can beformulated with Suitable 
polymeric or hydrophobic materials (for example as an emul 
sion in an acceptable oil) or ion exchange resins, or as spar 
ingly soluble derivatives, for example, as a sparingly soluble 
salt. 
The compositions can, if desired, be presented in a pack or 
dispenser device that can contain one or more unit dosage 
forms containing the active ingredient. The pack can for 
example comprise metal or plastic foil. Such as ablisterpack. 
The pack or dispenser device can be accompanied by instruc 
tions for administration. 
In certain preferred embodiments, the pack or dispenser 
contains one or more unit dosage forms containing no more 
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than the recommended dosage formulation as determined in 
the Physician's Desk Reference (62' ed. 2008, herein incor 
porated by reference in its entirety). 
Methods of administering the active compound and 
optionally another therapeutic or prophylactic agent include, 
but are not limited to, parenteral administration (e.g., intrad 
ermal, intramuscular, intraperitoneal, intravenous and Subcu 
taneous), epidural, and mucosal (e.g., intranasal, rectal, vagi 
nal, Sublingual, buccal or oral routes). In a specific 
embodiment, the active compound and optionally another 
prophylactic ortherapeutic agents are administered intramus 
cularly, intravenously, or Subcutaneously. The active com 
pound and optionally another prophylactic or therapeutic 
agent can also be administered by infusion or bolus injection 
and can be administered together with other biologically 
active agents. Administration can be local or systemic. The 
active compound and optionally the prophylactic ortherapeu 
tic agent and their physiologically acceptable salts and sol 
vates can also be administered by inhalation or insufflation 
(either through the mouth or the nose). In a preferred embodi 
ment, local or systemic parenteral administration is used. 
In specific embodiments, it can be desirable to administer 
the active compound locally to the area in need of treatment. 
This can be achieved, for example, and not by way of limita 
tion, by local infusion during Surgery or topical application, 
e.g., in conjunction with a wound dressing after Surgery, by 
injection, by means of a catheter, by means of a Suppository, 
or by means of an implant, said implant being in one embodi 
ment of a porous, non-porous, or gelatinous material, includ 
ing membranes, such as Silastic membranes, or fibers. 
Pulmonary administration can also be employed, e.g., by 
use of an inhaler or nebulizer, and formulation with an aero 
Solizing agent, or via perfusion in a fluorocarbon or synthetic 
pulmonary Surfactant. In certain embodiments, the active 
compound can be formulated as a Suppository, with tradi 
tional binders and vehicles such as triglycerides. 
Selection of a particular effective dose can be determined 
(e.g., via clinical trials) by a skilled artisan based upon the 
consideration of several factors, which will be known to one 
skilled in theart. Such factors include the disease to be treated 
or prevented, the symptoms involved, the subjects body 
mass, the Subject’s immune status and other factors known by 
the skilled artisan. 
The dose of the active compound to be administered to a 
Subject, Such as a human, is rather widely variable and can be 
Subject to independent judgment. It is often practical to 
administer the daily dose of the active compound at various 
hours of the day. However, in any given case, the amount of 
the active compound administered will depend on Such fac 
tors as the solubility of the active component, the formulation 
used. Subject condition (such as weight), and/or the route of 
administration. 
EXAMPLES 
The following examples are provided in order to demon 
strate and further illustrate certain preferred embodiments 
and aspects of the present invention and are not to be con 
Strued as limiting the scope thereof. 
In the experimental disclosure which follows, the follow 
ing abbreviations apply: N (normal); M (molar); mM (milli 
molar); LM (micromolar); mol (moles); mmol (millimoles); 
umol (micromoles); nmol (nanomoles); pmol (picomoles); g 
(grams); mg (milligrams); Lug (micrograms), ng (nanograms); 













ters); mm (millimeters); um (micrometers); nm (nanom 
eters); C (degrees Centigrade); TLC (thin layer chromatog 
raphy). 
Example I 
As shown in FIG. 3B (the specific route from 8 to 14), 
commercially available 8 was coupled to the boronic acid tris 
anhydride 9 using Suzuki reaction conditions to give 10 in 
96% yield. Treatment of 10 with ethylvinyl ether/Br2/diso 
propylamine/CH2Cl at 0°C. resulted in the ether 12 in 99% 
yield. 12 was then combined with CsP (3.22 eq) in dimethyl 
formamide under reflux conditions (130° C.) to give 14 in 
90% yield. The structure of 14 was determined via X-ray 
analysis. The overall yield from 8 to 14 via 10 and 12 is 85.5% 
for the three steps. In an alternative embodiment, the same 
sequence of reactions may be performed with the SiMeBut 
(tert-butyldimethylsilyl) protected phenol derivative 9a, 
which provides the cross-conjugated 2.5-cyclohexadienone 
14 in three steps from 8 via 11 and 13 in an overall yield of 
94.1% 
As shown in FIG. 4B (the specific route from 14 to 19), 
Treatment of 14 with nitromethane under Henry aldol reac 
tion conditions results in 15 at an unoptimized yield of 97% as 
a mixture (1:1) of epimers at the C site. These epimers were 
characterized by X-ray crystallography. It is noteworthy that 
only the correct cis-stereochemical relationship between the 
newly formed B-ring and the C-ring, i.e. at the C and Ca 
positions, is observed in 15. 
The stereogenic center at C in 15, 16 and 17 is eventually 
removed by the conversion of 17 into 18, as shown in FIG. 4B. 
Treatment of 15 with sodium cyanoborohydride gave 16 in 
90% yield, which on further reduction with lithium aluminum 
hydride gave 17 (72% yield). The intramolecular reductive 
amination of 17 gave 18. The yields in these conversions are 
not optimized, but are clean reactions with no discernible 
by-products. The compound 18 was characterized as the 
known carbamate derivative 19 from the Taber synthesis of 
morphine. 
The third and final phase involves the conversion of 19 into 
codeine 4. The prior literature dealing with this topic involves 
proceeding via codeinone 3 followed by reduction to 4. While 
not limiting the present invention to any particular theory, it is 
believed that the epoxidation of the 6,7-double bond proceeds 
from the least hindered face to give the R-epoxide, which 
eventually requires stereochemical inversion at C. As show 
in FIG. 5B, treatment of 19 with 3.3-dimethyl-1,5-dibromo 
hydantoin gave 20 (97% yield). Exposure to KOH and Ph.H 
under reflux conditions resulted in the B-epoxide 21 (93% 
yield) with concomitant bromination at the C position. Treat 
ment of 21 with PhSNa/EtOH gave 22 (99% yield), and the 
derived sulfoxide thermally eliminated to give 23 (93% 
yield). Reduction of 23 with LiAlH4/THF at 25° C. converted 
23 into codeine 4 (87% yield). 
Example II 
In the following example, melting points were taken on a 
Thomas-Hoover capillary tube apparatus, and are uncor 
rected. Infrared spectra were recorded on a Thermo-Nicolet 
Avatar 360 FT-IR spectrophotometer, with the sample neat on 
KBr plates, unless otherwise indicated. H and 'C NMR 
spectra were recorded on a General Electric QE-300 spec 
trometer at 300 MHz, in the indicated solvent, and are 
reported in ppm relative to tetramethylsilane, or referenced 
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internally to the residually protonated solvent. Mass spectra 
were obtained on a VGZAB2E, or a Finnigan TSQ70 mass 
spectrometer. 
Routine monitoring of reactions was performed using 
Merck 60 Fis glass-backed silica gel TLC plates. Flash col 
umn chromatography was performed using EMD Silica gel 
(particle size 0.040-0.063 um). Solvents and commercial 
reagents were purified as disclosed in Perrinet al. Purification 
of Laboratory Chemicals; 3" edition; Permagon Press: New 
York, 1993, or used without further purification. All reactions 
were conducted under an argon atmosphere, and solvents 




To a stirred solution of 4-bromophenol (25.1 g, 146 mmol), 
and imidazole (19.9 g, 292 mmol) in 1,2-dichloroethane (150 
mL) at 23°C. was added triisopropylsilylchloride (34.4 mL, 
161 mmol). The mixture was stirred for 12 hand poured onto 
saturated aqueous NHCl (400 mL), followed by extraction 
with CHCl (3x200 mL). The combined extracts were 
washed with brine (300 mL), dried (Na2SO), and concen 
trated in vacuo to give a pale yellow oil which was crude oil 
was purified via short-path distillation (0.5 mmHg, 130° C.) 
to yield (4-Bromo-phenoxy)-triisopropylsilane as a colorless 
oil (53.0 g.99% yield). R,081 (3:1 hexanes/EtOAc) IR (thin 
film) 2945,2892, 2867 cm. "H NMR (300 MHz, CDC1) & 
7.30 (2H, d, J=9 Hz), 6.75 (2H, d, J=9 Hz), 1.29-1.18 (3H, m), 
1.08 (18H, d, J=7 Hz). CNMR (75 MHz, CDC1) & 155.0, 
132.0, 121.5, 112.9, 17.6, 12.4. HRMS calcd. for 





To a stirred Suspension of isovanillin (10 g. 66 mmol), 
powdered anhydrous sodium acetate (10.82g, 0.132 mol) and 
iron powder (0.3 g, 5.4 mmol) in glacial acetic acid (60 mL) 
under argon, was added drop-wise over 15 min a solution of 
Br (3.7 mL, 0.0726 mol) in acetic acid (12.5 mL). The 
reaction temperature rose during the course of addition, and 
the mixture became Viscous. After all the starting material 
was consumed, as determined by TLC, the mixture was 
poured onto ice cold water, and the resulting precipitate fil 
tered under vacuum. The precipitate was washed several 
times with coldwater and air-dried. Crystallization from boil 
ing ethanol gave 8 (11.93 g, 79% yield) as a gray powder. 
R-0.10 (1:5 EtOAc/hexanes). Mp. 196-200° C. IR (thin 
film) 3215, 1662, 1588, 1561, 1491, 1273 cm. H NMR 
(300 MHz, CDC1) & 10.27(1H, s), 7.59 (1H, d, J=9 Hz), 6.96 
(1H, d, J=9 Hz), 6.02 (1H, bs), 4.00 (3H, s). 'C NMR (75 
MHz, CDC1) & 56.58, 109.24, 112.84, 113.84, 122.74, 
143.25, 151.65, 190.87. HRMS calcd. for CHO, Br (MH) 














To a solution of (4-bromo-phenoxy)-triisopropylsilane 
(18.6 g., 56.7 mmol) in dry THF (500 mL) at -78° C. was 
added drop-wise a solution of n-Bulli (45 mL, 79.4 mmol. 2.5 
M in THF). The resulting yellow solution was stirred 70 min 
at -78° C. before drop-wise addition of freshly distilled 
B(OPr) (36 mL, 160 mmol). The mixture was stirred 12 hat 
23°C. until all the starting material was consumed, as deter 
mined by thin layer chromatography (TLC). The mixture was 
combined with 10% aqueous KHSO (300 mL), and 
extracted with EtOAc (3x200 mL). The combined extracts 
were washed with brine (200 mL), dried (Na2SO) and con 
centrated in vacuo to yield an off-white solid. The crude solid 
was purified by flash column chromatography (SiO, 20% 
EtOAc/hexanes) to give a waxy white solid, which on 
azeotroping intoluene gave 9 (12.68 g, 76% yield) as a chalky 
white solid. Mp. 220° C. (hexanes). R, 0.51 (1:1 hexanes/ 
EtOAc). IR (thin film) 3035, 2944, 2892, 2867 cm'. 'H 
NMR (300 MHz, CDC1,) 88.11 (6H, d, J=8 Hz), 7.00 (6H, d, 
J=8 Hz), 1.35-1.28 (9H, m), 1.14 (54H, d, J=8 Hz). CNMR 
(75 MHz, CDC1) & 1599, 137.2, 122.6, 119.4, 17.7, 12.5. 
HRMS calcd. for CHBO Si (MH") 829.5229, found 
829.5227. 
6-Hydroxy-5-Methoxy-4-(Triisopropylsilanyloxy)- 
Biphenyl-2-Caribaldehyde (R = TIPS) (10) 
OR 




To a degassed (30 min) mixture of 1,4-dioxane (9 mL) and 
water (4 mL) was added powdered KCO (1.13 g, 8.16 
mmol), 8 (0.687 g, 2.99 mmol), 9 (0.750 g, 2.72 mmol), 
2,6-di-tert-butyl-4 methylphenol (BHT) (0.300 g, 1.36 
mmol), and tricyclohexylphoshine (61 mg 0.218 mmol). The 
mixture stirred for 15 min at 23°C. and Pd(dba) (0.100 g, 
0.109 mmol) was added, and then heated at reflux for 1 huntil 
all starting material was consumed, as determined by thin 
layer chromatography (TLC). The resulting dark colored 
mixture was poured onto saturated aqueous NHCl (20 mL) 
and extracted with EtOAc (5x25 mL). The combined extracts 
were washed with brine (20 mL), dried (NaSO) and con 
centrated in vacuo to yield an orange oil. The crude oil was 
purified via flash column chromatography (SiO2, 20% 
EtOAc/hexanes) to give 10 (1.05 g, 96% yield) as a thick 
yellow-orange oil. R, 0.61 (CH2Cl2). IR (thin film) 3538, 
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2945, 2892, 2867, 1683 cm'.' H NMR (300 MHz, CDC1,) 
& 9.68 (1H, s), 7.64 (1H, d, J=9 Hz), 7.26-7.22 (2H, m), 
7.01-6.96 (3H, m), 5.68 (1H, s), 4.01 (3H, s), 1.33-1.26 (3H, 
m), 1.13 (18H, d, J=7 Hz). 'C NMR (75 MHz, CDC1,) & 
1914, 155.8, 150.8, 142.3, 131.7, 129.1, 128.2, 124.5, 120.6, 
119.5, 109.2, 56.0, 17.7, 12.5. HRMS calcd. for CHOSi 
(MH") 401.2148, found 4.01.2148. 
6-(2-Bromo-1-Ethoxy-Ethoxy)-5-Methoxy-4-Triisopropylsilanyloxy)- 






(R = TIPS, 99%) 
12 
To a solution of bromine (0.91 mL, 17.8 mmol) in CHC1. 
(50 mL) at 0°C. was added drop-wise ethyl vinyl ether (2.13 
mL, 22.2 mmol). The resulting colorless Solution was stirred 
for 20 min at 0°C. and N,N-diisopropylamine (DIEA) (6.23 
mL, 35.6 mmol) added drop-wise, followed by a CHCl (20 
mL) solution of 10 (3.55g, 8.9 mmol). The resulting solution 
was stirred for 16 hat 23°C., until all starting material was 
consumed, as determined by TLC. The mixture was poured 
onto saturated aqueous NaHCO (100 mL), and extracted 
with CHCl (3x70 mL). The combined extracts were washed 
with brine (80 mL), dried (NaSO), and concentrated in 
vacuo to yield orange oil. The crude oil was purified via flash 
column chromatography (SiO2, 10% EtOAc/hexanes) to give 
12 (4.84g, 99% yield) as a thick orange oil. R, 0.52 (3:1 
hexanes/EtOAc). IR (thin film) 2966,2944, 2892, 2867, 1684 
cm'. 'H NMR (300 MHz, CDC1) & 9.64 (1H, s), 7.85 (1H, 
d, J=8 Hz), 7.25-7.18 (2H, m), 7.03 (1H, d, J=8 Hz), 6.96 (2H, 
d, J=8 Hz), 5.06-5.02 (1H, m), 3.98 (3H, s), 3.65-3.55 (1H, 
m), 3.42-3.34 (1H, m), 3.12-3.01 (2H, m), 1.35-1.20 (3H, m), 
1.13 (18H, d, J=7 Hz), 1.05 (3H, t, J=7 Hz). 'C NMR (75 
MHz, CDC1) & 1911, 156.9, 156.1, 141.5, 140.5, 1324, 
128.4, 125.1, 119.4, 113.6, 111.0, 103.5, 64.5, 55.9, 31.7, 
17.8, 14.9, 12.5. HRMS calcd. for CHOSiBr (MH") 
551.1828, found 551.1821. 






(90% from 12) 
A suspension of dry CsF (0.490 g, 3.22 mmol) and 12 













A molecular sieves) were heated at reflux for 2 h. After all 
starting material was consumed, as determined by TLC, the 
mixture was poured onto saturated aqueous NaHCO (100 
mL) and extracted with EtOAc (3x70 mL). The combined 
extracts were washed with brine (80 mL), dried (NaSO), 
and concentrated in vacuo to yield orange oil which was 
purified via flash column chromatography (SiO, 25% 
EtOAc/hexanes) to give 14 (0.302 g, 90% yield) as thick 
orange oil which Solidified upon standing to a orange solid. 
M. p. 74-80° C. R-0.23 (1:1 EtOAc/hexanes). IR (thin film) 
2983, 2932, 2889, 1684, 1663, 1586 cm. H NMR (300 
MHz, CDC1) 89.95 (s, 1H), 7.75 (1H, dd, J’s=10, 3 Hz), 7.64 
(1H, d, J=9 Hz), 7.04 (1H,J’s=10, 3 Hz), 6.98 (1H, d, J=9 Hz), 
6.38 (1H, dd, J’s=8, 2 Hz), 6.36 (1H, dd, J’s=8, 2 Hz), 5.15 
(1H, t, J-2 Hz), 4.00 (s.3H), 3.96 (1H, m), 3.70 (1H, m), 2.40 
(1H, dd, J’s=14, 2 Hz), 2.01 (1H, dd, J’s=14, 2 Hz), 1.22 (3H, 
t, J–7 Hz). CNMR (75 MHz, CDC1) & 189.6, 1844, 155.8, 
155.5, 154.5, 140.1, 128.7, 126.0, 123.3, 122.8, 110.7, 94.8, 
64.7, 56.2, 40.2, 39.8, 15.0. HRMS calcd. for C.H.O. 




To a stirred solution of p-bromophenol (30 g, 0.1734 mol) 
in 1, 2-dichloroethane (300 mL) at 23°C. was added imida 
Zole (29.45 g, 0.433 mol). After 15 min, tert-butyldimethyl 
silylchloride (28.75 g, 0.190 mol) was added, and the result 
ing solution heated at reflux for 3 h. The mixture was cooled 
to room temperature and poured onto saturated aqueous 
NHCl and extracted with CHCl (3x200 mL). The com 
bined extracts were washed with brine (200 mL), dried 
(NaSO), filtered and evaporated in vacuo. The crude product 
was distilled via short-path distillation (0.5 mm Hg, 130°C.) 
to give (4-bromo-phenoxy)-tert-butyl-dimethylsilane (49.6 
g, 99.5% yield) as a colorless oil. R, 0.80 (1:3 EtOAc/hex 
anes). IR (thin film) 3390, 2951, 2928, 1584, 1479, 1250 
cm'. 'H NMR (300 MHz, CDC1) & 7.34 (1H, d, J=9 Hz), 
6.74 (1H, d, J=9 Hz), 1.00 (12H, s), 0.21 (6H, s). 'C NMR 
(75 MHz, CDC1,) & 15476, 132.22, 121.83, 113.55, 25.58, 
18.12, -4.54. HRMS calcd. for CHBrOSi (MH) 
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To a solution of (4-bromo-phenoxy)-tert-butyl-dimethyl 
silane (10g, 35 mmol) in THF (25 mL) at -78°C. was added 
drop-wise n-butyllithium (2.4 M in hexanes, 17.5 mL, 42 
mmol) resulting in a yellow colored solution. After stirring 
the mixture for 30 min, freshly distilled triisopropoxyborate 
(24.2 mL, 105 mmol) was added drop-wise to the above 
Solution, and the mixture was stirred overnight and allowed to 
warm to room temperature. The mixture was poured onto 
10% aqueous KHSO (50 mL) and extracted with EtOAc 
(3x150 mL). The combined extracts were washed with brine 
(200 mL), dried (NaSO), filtered and evaporated in vacuo. 
The crude white solid was dried by azeotroping in toluene 
(3x20 mL), and recrystallized from hexanes/EtOAc to give 
needle shaped crystals of 9a (6.9 g, 84.5% yield). M. p. 118 
120° C. R-0.12 (1:5 EtOAc/hexanes). IR (thin film) 2955, 
2928, 2854, 1592 cm'. 'H NMR (300 MHz, CDC1,) & 8.13 
(2H, d, J=8 Hz), 6.97 (2H, d, J=8 Hz), 1.03 (9H, s), 0.27 (2H, 
s). ''C NMR (75 MHz, CDC1) & 159.7, 1374, 119.8, 25.7, 
18.3, -4.3. HRMS calcd. for CHBO Si (MH") 
703.3820, found 703.3826. 
4'-(Tert-Butyl-Dimethyl-Silanyloxy)-6-Hydroxy 





(R = TBDMS, 87.9%) 
To a degassed (30 min) mixture of 1,4-dioxane (22.5 mL) 
and water (7.5 mL) was added powdered KCO (2.48 g. 18 
mmol), 8 (1.53 g. 6.6 mmol), 9a (1.5 g. 6 mmol), 2,6-di-tert 
butyl-4 methylphenol (BHT) (spatula), and tricyclohexy 
lphoshine (67 mg, 0.24 mmol). The mixture stirred for 15 min 
at 23° C. and Pd(dba) (0.114 g., 0.12 mmol) was added, 
and then heated at reflux for 1 huntil all starting material was 
consumed, as determined by TLC. The resulting dark colored 
solution was poured onto saturated aqueous NHCl (200 mL) 
and extracted with EtOAc (3x150 mL). The combined 
extracts were washed with brine (200 mL), dried (Na2SO) 
and concentrated in vacuo to yield a yellow solid. Purification 
by flash column chromatography (SiO, 15% EtOAc/hex 
anes) gave 11 (2.1 g, 87.9% yield) as a pale yellow solid. M.p. 
103-106° C. R-0.20 (1:5 EtOAc/hexanes). IR (thin film) 
3401, 2930, 2857, 1684 cm. "H NMR (300 MHz, CDC1,) & 
9.69 (1H, s), 7.65 (1H, d, J=9 Hz), 7.24 (1H, d, J=9 Hz), 6.98 
(1H, d, J=9 Hz), 6.95 (1H, d, J=9 Hz), 5.67 (1H,bs), 4.02 (3H, 
s), 1.02 (9H, s), 0.26 (6H, s). 'c NMR (75 MHz, CDC1) & 
1916, 155.7, 150.8, 142.7, 132.0, 131.5, 128.4, 120.5, 119.8, 
109.6, 56.2, 25.6, 18.2, -4.4. HRMS calcd. for C.H.O.Si 
(MH)359,1679, found 359,1675. 
Conducting the above reaction on the following scale— 
KCO (4.48g, 32.4 mmol), 8 (2.75 g, 11.88 mmol), 9a (2.54 
g, 10.8 mmol), 2,6-di-tert-butyl-4 methylphenol (BHT) (1.19 
g, 5.4 mmol), tricyclohexylphoshine (0.24 g., 0.864 mmol), 
Pd(dba) (0.40 g, 0.432 mmol) in dioxane (36 mL) and 




















(R = TBDMS, 92%) 
13 
To a solution of Br (0.397 mL, 7.74 mmol) in CHCl (30 
mL) at 0°C. was added drop-wise ethyl vinyl ether (0.92 mL, 
9.68 mmol) until the solution turned colorless. The mixture 
was stirred for 15 min and diisopropylethylamine (2.71 mL, 
15.48 mmol) was added followed by a drop-wise addition of 
a solution of 11 (1.5g, 3.87 mmol) in CHCl (15 mL). The 
mixture was stirred for 12 h under an argon atmosphere to 
give an orange-red solution. After complete consumption of 
staring material, as determined by TLC. the mixture was 
poured onto saturated aqueous NaHCO and extracted with 
CHCl (3x50 mL). The combined extracts were washed with 
brine (100 mL), dried (Na2SO), filtered and evaporated in 
vacuo to give an orange-red oil. Purification by flash column 
chromatography (SiO, 10% EtOAc/Hexanes) gave 13 (1.92 
g.92% yield) as a colorless syrupy liquid. (1.92g.92% yield). 
R-0.42 (1:5 EtOAc/hexanes). IR (thin film) 2956, 2930, 
2857, 1684 cm. "H NMR (300 MHz, CDC1) 89.64 (1H, s), 
7.85 (1H, d, J=9 Hz), 7.25-7.18 (2H, m), 7.03(1H, d, J=9 Hz), 
6.93 (2H, d, J=9 Hz), 5.01 (1H, dd, J’s=7, 4 Hz), 3.98 (3H, s), 
3.56 (1H, m), 3.31 (1H, m), 3.09 (2H, m), 1.05 (2H, t, 7 Hz), 
1.01 (9H, s), 0.24 (6H, s). ''C NMR (75 MHz, CDC1) & 
1915, 157.02, 155.8, 1417, 140.6, 132.5, 128.5, 125.2, 
119.7, 111.0, 103.7, 64.5, 55.9, 31.8, 25.6, 18.2, 14.9, -4.4. 
HRMS calcd. for CHOSiBr (MH") 509. 1359, found 
5091356. 
Conducting the above reaction on the following scale—Br. 
(1.64 mL, 32 mmol) in CHCl (126 mL), ethyl vinyl ether 
(3.8 mL, 40 mmol), diisopropylethylamine (11.2 mL. 64 
mmol) 11 (5.73 g, 16 mmol) gave 13 (8.10g, 99% yield). 






(95.5% from 13) 
A flame-dried mixture of CsF (0.22 g, 1.44 mol) and 
NaSO (0.68 g, 4.8 mmol) was added to a solution of 13 
(0.26g, 0.48 mmol) in DMF (3.7 mL, stored over 4A molecu 
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lar sieves) and the reaction mixture was heated at 130°C. for 
1.5 h. After completion of the reaction, as determined by 
TLC, the reaction mixture was poured into saturated aqueous 
NaHCO, (25 mL) and extracted with EtOAc (4x20 mL). The 
combined extracts were successively washed with water 
(3x25 mL), brine (50 mL), dried (Na2SO), filtered and con 
centrated in vacuo to give a brown syrup. Purification by flash 
chromatography (SiO, 30% EtOAc/hexanes) gave com 
pound 14 (0.137 g, 95.5% yield). 
Conducting the above reaction on the following scale: 13 
(7.0g, 13.8 mmol), CsP (6.5g, 41.3 mmol) in DMF (138 mL) 




















A mixture of the dienone 14 (1.0 g, 3.18 mmol), NHOAc 
(0.98 g. 12.7 mmol), and nitromethane (1.01 mL, 19.08 
mmol) in acetic acid (15 mL) was heated at reflux for 2 h. 
After completion of the reaction, as determined by TLC, the 
Solvent was evaporated in vacuo and the residue was washed 
with water (40 mL) and extracted with diethylether (3x50 
mL). The combined extracts were washed with brine (50 mL), 
dried (Na2SO4), filtered and concentrated in vacuo to give a 
brown solid. Purification by flash chromatography (SiO, 
20% EtOAc/hexanes) gave bright yellow crystals of the two 
diastereomers 15 and 15a (0.72 g. 63% yield) in approxi 
mately 1:1 ratio. Data for 15. R, 0.47 (1:1 EtOAc/hexanes). 
M. p. 165-170° C. IR (thin film) 2920,2842, 1685, 1565 cm. 
'HNMR (300 MHz, CDC1) & 7.56 (1H, d, J–2Hz), 6.96 (1H, 
d, J–8 Hz), 6.86 (1H, d. J=8 Hz), 6.48 (1H, dd, J’s=10, 2 Hz), 
5.98 (1H, d, J=10 Hz), 5.38 (1H, dd, J’s=9, 3 Hz), 4.16 (1H, 
m), 3.92 (3H, s), 3.74 (1H, m), 3.50 (1H, m), 3.28 (1H, dd, 
J’s=6, 2 Hz), 2.89 (1H, dd, J’s=18, 5 Hz), 2.66 (1H, dd, 
J’s=13, 3 Hz), 2.27 (1H, dd, J’s=13, 9 Hz), 1.29 (3H, t, J=7 
Hz). 'C NMR (75 MHz, CDC1) & 1946, 150.0, 146.9, 
1414, 132.2, 128.7, 123.9, 121.3, 111.3, 97.7, 65.3, 56.1, 
42.1, 39.1, 38.8, 34.2, 15.1. HRMS calcd. for CHNO 
(MH)358.1291, found 358.1290. 
Data for 15a. R-0.47 (1:1 EtOAc/Hexanes). Mp. 161 













NMR (300 MHz, CDC1) & 7.58 (1H, d, J=2 Hz), 7.00 (1H, d, 
J=9 Hz), 6.90 (1H, d, J=9 Hz), 6.75 (1H, dd, J’s=10, 1.5 Hz), 
5.92 (1H, d, J=10 Hz), 5.59 (1H, d, J=3 Hz), 3.95 (1H, m), 
3.96 (3H, s), 3.70 (1H, m), 3.45 (1H, dd, J’s 4, 2 Hz), 3.27 
(1H, dd, J–9, 1.5 Hz), 2.88 (1H, dd, J=18, 5 Hz), 2.70 (1H, dd, 
J’s=13, 1.5 Hz), 2.33 (1H, dd, J’s=13, 3 Hz), 1.20 (3H, t, J=7 
Hz). 'C NMR (75 MHz, CDC1,) & 1949, 1523, 1474, 
140.4, 132.2, 126.9, 123.9, 121.3, 110.9, 96.2, 68.1, 64.6, 
56.1, 43.1, 37.2, 36.2, 34.4, 29.64, 15.1. 
Example III 
To the dienone 14 (5.0 g, 15.93 mM) in nitromethane (50 
mL), was added NHOAc (0.5 g) and acetic acid (5 mL) and 
the solution was heated at reflux for 2.5 h. When 14 had been 
consumed (TLC), the mixture was poured into brine (50 mL) 
and the layers separated. The aqueous layer was successively 
washed with ether (2x40 mL). The combined organics were 
dried (NaSO) and concentrated in vacuo to give (5.5 g.97% 
yield) of 15/15a as a racemic mixture of two diastereomers in 
a 1:1 ratio. NMR analysis indicated that the crude mixture 





'' 16 EtON 
16a 
1:1.88% 
To a solution of the nitroalkenes 15/15a (127 mg, 0.36 
mmol) in THF (3.5 mL) and phosphate buffer (pH 4.5, 1.5 
mL) at 0°C. was added NaBHCN (23.5 mg, 0.37 mmol) in 
Small portions, and the resulting solution was stirred for 1 h 
until all the starting material was consumed as determined by 
TLC. The mixture was combined with aqueous NHCl (5 ml) 
and extracted with EtOAc (3x5 mL). The combined organic 
extracts were washed with brine (15 mL), dried (NaSO), 
filtered and concentrated in vacuo to give a pale yellow solid. 
Purification by flash column chromatography (SiO, 30% 
EtOAc/hexanes) gave 16 and 16a as white solids (112 mg, 
88% yield). R-0.55 (1:1 EtOAc/Hexanes). Data for 16. M.p. 
168° C. IR (thin film) 2975,2932, 1684, 1551 cm. "H NMR 
(300 MHz, CDC1) & 6.84 (1H, d, J=9 Hz), 6.82 (1H, dd, 
J’s=10, 4 Hz), 6.73 (1H, d. J=9 Hz), 6.06 (1H, d, J=10 Hz), 
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5.50 (1H, dd, J’s=8, 6 Hz), 4.92 (1H, m), 4.10 (1H, m), 3.88 
(3H, s), 3.67 (1H, m), 3.33 (2H, m), 2.86 (3H, m), 2.46 (1H, 
d, J=18 Hz), 2.00 (1H, dd, J’s=13, 8 Hz), 0.26 (3H, t, J–7 Hz). 
'C NMR (75 MHz, CDC1) & 1940, 1520, 148.6, 141.0, 
128.5, 125.2, 122.2, 121.5, 112.5, 98.2, 83.8, 64.4, 56.2, 43.6, 
42.4, 38.1, 35.9, 33.2, 14.9. HRMS calcd. for CHNO 
(MH)360.1447, found 360.1443. 
Data for 16a. R-0.55 (1:1 EtOAc/Hexanes). Mp. 201° C. 
IR (thin film) 2975, 2932, 1685, 1551 cm'. 'H NMR (300 
MHz, CDC1) & 6.87 (2H, m), 6.06 (1H, d, J=10 Hz), 5.50 
(1H, dd, J's=8, 6 Hz), 4.92 (1H, m), 4.10 (1H, m), 3.88 (3H, 
s), 3.67 (1H, m), 3.33 (2H, m), 2.86 (3H, m), 2.46 (1H, d, J=18 
Hz), 2.00 (1H, dd, J’s=13, 8 Hz), 0.26 (3H, t, J=7 Hz). 'C 
NMR (75 MHz, CDC1) & 1940, 152.0, 148.6, 1410, 128.5, 
125.2, 122.2, 121.5, 112.5, 98.2, 83.8, 64.4, 56.2, 43.6, 42.4, 
38.1, 35.9, 33.2, 29.6, 14.9; HRMS calcd. for CHNO 






To a solution of the nitroalkanes 16/16a (46.8 mg, 1.3 
mmol) in THF (15 ml) cooled to -78°C. under argon, was 
added LiAlH4 (2M in THF, 3.9 mL) drop-wise over a 20 
minute interval. The resulting solution was stirred at -78°C. 
for 1 h and allowed to warm to room temperature (RT) over 8 
h. The reaction was checked for completion by TLC, and then 
added to saturated aqueous NaSO (5 ml) at 0°C. The salts 
were filtered through a Buchner funnel and washed with (100 
ml) of ether. The organic layer was washed with brine (15 ml), 
dried (NaSO), and concentrated in vacuo to yield a pale 
yellow foamy solid. The crude product can be purified by 
column chromatography (SiO, 1% NEt, 10% MeOH, 89% 
CH,Cl) to yielda white foamy solid (312 mg, 72%). R, 0.26 
(15% MeOH/CH,Cl). Data for 17. IR (thin film)3352,3287, 
2924, 1497, 1439 cm. "H NMR (300 MHz, CDC1) & 6.84 
(1H, d, J=8 Hz), 6.71 (1H, d, J=9 Hz), 6.00 (1H, d. J=10 Hz), 
5.90 (1H, dd, J’s=10, 3 Hz), 5.50 (1H, dd, J’s=8, 6.6 Hz), 
4.42-4.17 (1H, m), 4.11-4.05 (1H, m), 3.86 (3H, s), 3.83-3.61 
(1H, m), 3.42-3.90 (1H, m), 3.05 (1H, dd, J’s=16, 3 Hz), 2.76 
(1H, dd, J’s=16.3 Hz), 2.60 (1H, dd, J’s=12.5, 6 Hz), 2.50 
(1H, m), 2.02 (2H, m), 2.02 (1H, bd, 15 Hz), 1.57 (1H, dd, 
J’s=12.5, 8 Hz), 1.21 (3H, t, J–7 Hz). 'C NMR (75 MHz, 













111.6, 99.2, 65.8, 64.2, 59.8, 56.2, 49.8, 44.8, 38.2, 34.6, 31.1, 
15.1. HRMS calcd. for CHNO (MH)332.1859, found 
332.1856. 
Data for 17a. R-021 (15% MeOH/CH,Cl). IR (thin film) 
3342,3287,2924, 2856, 1493, 1441, 1375, 1260, 1210, 1123, 
1035, 1009 cm'. 'H NMR (300 MHz, CDC1) & 6.77(1H, d, 
J=8 Hz), 6.69 (1H, d, J=8 Hz), 5.89 (1H, d, J=10 Hz), 5.90 
(1H, d, J=10 Hz), 5.50 (1H, d, J-2 Hz), 4.44-4.37 (1H, m), 
4.05-3.90 (1H, m), 3.86 (3H, s), 3.85-3.62 (1H, m), 3.26 (1H, 
m), 2.97 (2H, m), 2.67-2.34 (3H, m), 2.21 (2H, dd, J’s=17.7 
Hz), 2.02-1.86 (1H, m), 1.61 (1H, bs), 1.21 (3H, t, J–7 Hz). 
'C NMR (75 MHz, CDC1) & 147.4, 140.6, 135.9, 128.1, 
127.0, 125.6, 120.8, 110.4, 97.7, 64.3, 64.2, 56.2, 50.1, 45.8, 
42.2, 38.1, 34.7, 33.1, 15.2. 
Core Secondary Amine (18) 
18 
(66%) 
To a solution of the primary amines 17/17a (1.0 g, 3.02 
mM) in dioxane (48 mL) was added 1N HCl (16 mL) and 
stirred for 10 min NaCNBH (569 mg, 9.06 mM) was added 
in 3 portions after every 1 h. The mixture was taken to reflux 
and heated at reflux for 5 h. The pH was maintained between 
2-3 by adding 1 NHCl as required. The reaction was checked 
for completion by TLC, cooled to RT, and basified to pH10 
with 1M NaOH (aq) and extracted with diethyl ether (5x25 
mL). The combined organics were washed with brine (30 
mL), dried (Na2SO4) and conc. in vacuo to yield a brown 
syrup (730 mg). The crude product can be purified by column 
chromatography (SiO, 1% NEt, 10% MeOH, 89% CHCl) 
to yield pure 18 as a colorless syrup (540 mg. 66% yield). 
R-0.12 (15% MeOH/CH,Cl). IR (thin film) 3307, 3024, 
2920, 2847, 1634, 1504,1439, 1278, 1256, 1194, 1159, 1127, 
1063, 1037 cm. "H NMR (300 MHz, CDC1) & 6.71 (1H, d, 
J=8 Hz), 6.30 (1H, d, J–8 Hz), 5.86 (1H, m), 5.71 (1H, m), 
4.93 (1H, s), 3.86 (3H, s), 3.43 (1H, m), 3.00 (1H, dd, J’s=12, 
6 Hz), 2.84 (2H, m), 2.76 (1H, d, J=18 Hz), 2.35 (1H, m), 1.96 
(1H, t, J-6 Hz), 1.90 (1H, t, J=6 Hz), 1.80 (1H, m), 1.45 (1H, 
m). CNMR (75 MHz, CDC1) & 144.6, 143.1, 1319, 129.5, 
127.1, 124.5, 118.4, 112.7, 87.7, 56.1, 51.9, 49.9, 41.5, 39.1, 
38.8, 30.7, 24.4. HRMS calcd. for CHNO (MH") 
270.1494, found 270.1498. 
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To a solution of the secondary amine 18 (0.70g, 2.6 mmol) 
in CHCl (20 ml) cooled to 0°C. was added triethylamine 
(1.81 mL, 13.0 mmol) and ethyl chloroformate (0.62 mL, 6.5 
mmol) dropwise over 2 min. The resulting solution was 
stirred at 0°C. for 1 hour. After checking for completion by 
TLC, the reaction mixture was quenched with Saturated aque 
ous NHCl (20 mL) and extracted with CHCl (3x20 mL). 
The combined extracts were washed with brine (25 mL), 
dried (Na2SO4) and evaporated in vacuo to give a pale yellow 
oil. The crude product can be purified by column chromatog 
raphy (SiO, 30% EtOAc/hexanes) to yield a colorless syrup 
(0.795 g, 89.6% yield). R-0.48 (30% EtOAc/hexanes). IR 
(thin film) 2978, 2931, 2838, 1695 cm. "H NMR (300 MHz, 
CDC1,) & 6.73 (1H, d, J=8 Hz), 6.62 (1H, d, J=8 Hz), 5.85 
(1H, m), 5.71 (1H, d, J=10 Hz)), 4.95 (1H, s), 4.71 (major 
amide rotamer 0.60H, bs), 4.56 (minor amide rotamer 0.4H, 
bs), 4.15 (2H, q, J=7.2 Hz), 4.1-3.93 (1H, m), 3.85 (3H, s), 
3.06-2.86 (2H, m), 2.68 (1H, d, J-18 Hz), 2.30-2.25 (1H, m), 
2.00 (1H, dt, J's=18, 6 Hz), 1.90-1.70 (2H, m), 1.53-140 (1H, 
m), 1.27(3H, t, J–7.2 Hz). CNMR (75 MHz, CDC1,) Major 
rotamer: 6155.4, 144.9, 143.4, 131.9, 128.5, 125.8, 124.4, 
118.9, 113.3, 87.4, 61.4, 56.2, 50.1, 41.1, 37.7, 35.0, 28.8, 
24.0, 14.7. Minor rotamer: & 155.0, 144.8, 143.4, 131.6, 
128.5, 125.6, 124.6, 118.9, 113.3, 87.4, 61.4, 56.2, 50.5, 41.1, 
37.7, 34.8, 29.0, 24.1, 14.6. HRMS calcd. for CHNO 





To a solution of 19 (250 mg, 0.73 mmol) in acetone/HO 
(10:1, 11 mL) was added recrystallized 2.2 bromo-3.5 dim 
ethylhydantoin (520 mg, 1.83 mmol) in small portions over 5 
min. The entire set-up was covered with aluminum foil, 
placed in the dark and stirred for 12 h until all the starting 
material was consumed as determined by TLC. The reaction 
mixture was quenched with saturated NHCl (10 ml), diluted 
with water (10 ml) and extracted with ethyl acetate (3x15 ml). 
The combined extracts were washed with brine (20 mL), 
dried (Na2SO) and evaporated in vacuo to give a yellow oil. 
The crude product can be purified by column chromatogra 
phy (SiO, 50% EtOAc/hexanes) to yield a colorless syrup 
(365 mg, 97%) or can be carried forward onto the next step 
without purification. R, 0.26 (1:1 EtOAc/hexanes). IR (thin 
film) 3420, 2978, 2937, 2889, 1684 cm'. 'H NMR (300 
MHz, CDC1) & 6.98 (1H, s), 4.83 (1H, d, J–7 Hz), 4.78 
(Major rotamer 0.60H, bs), 4.63 (Minor rotamer 0.4H, bs), 
4.11 (2H, q, J=7.2 Hz), 4.1-3.94 (1H, m), 3.89 (3H, s), 3.72 
2.59 (2H, m), 2.77-2.61 (1H, m), 2.52 (1H, bs), 2.00 (1H, dt, 
J’s=17, 3.7 Hz), 2.20 (1H, m), 1.75-1.70 (1H, m), 1.27 (3H, t, 
J=7.2 Hz); 1.07-0.95 (H, m). ''C NMR (75 MHz, CDC1,) 
Major rotamer: & 155.4, 145.1, 143.3, 129.3, 125.2, 117.7, 
113.5, 95.8, 70.5, 61.8, 60.4, 56.8, 50.2, 45.4, 38.4, 37.8, 34.4, 
31.9, 29.8, 14.6. Minor rotamer: & 155.0, 145.1, 143.3, 129.3, 
125.2, 117.7, 113.5, 95.8, 70.2, 61.7, 60.4, 56.8, 50.6, 45.4, 
38.3, 38.2, 34.1, 31.9, 30.1, 14.7. HRMS calcd. for 
















(93% from 19) 
To a solution of the bromohydrin 20 (365 mg 0.71 mM) in 
toluene (15 mL) was added, solid KOH (200 mg) and the 
mixture was heated at 80°C. for 3 hours until all the starting 
material was consumed (TLC). The reaction mixture was 
cooled and diluted with water (15 ml) and extracted with ethyl 
acetate (3x20 mL). The combined organics were washed with 
brine (10 mL), dried (NaSO) and conc. in vacuo to give a 
yellow oil. The crude product was purified by column chro 
matography (SiO, 40% EtOAc/hexanes) to yield 21 as a 
colorless syrup (295 mg, 95.6%). R, 0.37 (1:1 EtOAc/hex 
anes). IR (thin film) 2963, 2926, 2850, 1695, 1684 cm. "H 
NMR (300 MHz, CDC1) & 6.91 (1H, s), 4.87 (1H, d, J=3.7 
HZ), 4.70 (major amide rotamer 0.70H. bs), 4.56 (minor 
amide rotamer 0.3H, bs), 4.13 (2H, q, J=7.3 Hz), 4.1-3.89 
(1H, m), 3.86 (3H, s), 3.30-2.23 (2H, m), 2.79-2.70 (2H, m), 
2.53 (1H, d, J-18 Hz), 2.00 (2H, m), 1.79-1.68 (2H, m), 1.27 
(3H, t, J=7.2 Hz); 1.15-1.06 (H, m). 'C NMR (75 MHz, 
CDC1) Major rotamer: 8155.2, 146.1, 142.9, 129.2, 124.2, 
116.7, 112.0, 87.6, 61.4, 56.4, 53.5, 50.9, 49.8, 41.1, 37.3, 
36.2, 35.9, 29.9, 22.7, 14.5. Minor rotamer: & 154.8, 146.1, 
142.9, 129.2, 124.0, 116.7, 112.0, 87.6, 61.5, 56.5, 53.5, 50.9, 
50.2, 41.1, 37.2, 36.3, 35.9, 30.2, 22.9, 14.6. HRMS calcd. for 
CHBrNOs (MH)436.0760, found 436.0758. 
Alternatively, the epoxides 21 may be obtained by mixing 
a solution of the carbamate 19 (70 mg, 0.205 mM) in 14 
dioxane (3 mL) and water (1 mL) and further adding recrys 
tallized 1.3 bromo-5.5 dimethyl hydantoin (60.0 mg, 0.21 
mM) and stirring for 12 hours in the dark. After 19 was 
consumed (TLC), solid KOH (50 mg) was added and the 
solution was heated at 80°C. for 2.5 h. After all the interme 
diate bromohydrin 20 was consumed (TLC), the solution was 
diluted with water (10 mL) and extracted with ethyl acetate 
(3x10 mL). The combined organics were washed with brine 
(10 mL), dried (Na2SO4) and concentrated in vacuo to give a 
pale, yellow oil. The crude product was purified by column 
chromatography (SiO, 40% EtOAc/hexanes) to yield 21 as a 
colorless syrup (81 mg, 91%). 
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To a solution of diphenyl disulfide (12 mg, 0.055 mmol) in 
EtOH (1.0 mL) was added NaBH (4 mg., 0.11 mmol) portion 
wise over 5 min. The resulting solution was stirred for 15 min 
and then added drop-wise to a solution of the epoxide 21 (16 
mg, 0.037 mmol) in EtOH (1.0 mL). The resulting solution 
was stirred at 25° C. for 2 huntil all the substrate was con 
sumed (TLC). The mixture was diluted with water (5 mL) and 
extracted with CHCl (3x5 mL). The combined organics 
were washed with brine (5 mL), dried (NaSO) and conc. in 
vacuo to give a pale yellow solid. The crude product was 
purified by column chromatography (SiO, 30% EtOAc/hex 
anes) to yield 22 as a white solid (20 mg.99% yield). R, 0.60 
(40% EtOAc/hexanes). IR (thin film) 3446, 2936, 1684, 
1487, 1437, 1323, 1300, 1274, 1229, 1191, 1172, 1148, 1065, 
1023 cm. H NMR (300 MHz, 
CDC1) & 7.39 (2H, d, J–7.3 Hz), 7.30 (3H, m), 6.93 (1H, 
s), 4.88 (1H, d, J=5 Hz), 4.69 (Major rotamer 0.60H, bs), 4.54 
(Minor rotamer 0.4 H, bs), 4.14 (2H, q, J–7.2 Hz), 4.07-3.91 
(2H, m), 3.84 (3H, s), 3.36–3.28 (2H, m), 2.79-2.59 (2H, m), 
2.39-2.34 (2H, m), 1.85-1.56 (4H, m), 1.27 (3H, t, J=7.2 Hz); 
'C NMR (75 MHz, CDC1) Major rotamer: 6155.3, 145.8, 
142.8, 132.3, 129.2, 127.7, 125.1, 116.6, 112.8, 89.0, 68.4, 
61.5, 60.3, 56.4, 50.5, 46.5, 42.5, 37.6, 36.2, 36.0, 29.9, 24.4, 
21.0, 14.6; Minor rotamer: & 155.0, 145.8, 142.8, 133.2, 
132.0, 130.7, 129.2, 127.7, 124.8, 116.6, 112.8, 89.0, 68.4, 
61.6, 56.4, 51.0, 46.5, 42.3, 37.6, 36.4, 35.7, 30.1, 24.4, 14.7: 
HRMS calcd. for CHBrNOS (MH) 568.0758, found 
568.0764. 
Allylic Alcohol (23) 
23 
(93%) 
To a solution of 22 (20 mg, 0.036 mmol) in hexafluoroiso 
propanol (0.5 mL) was added hydrogen peroxide (30% aq. 
0.05 mL) and the resulting solution was stirred for 15 min 
until all starting material was consumed (TLC). The reaction 
mixture was diluted with water (5 ml) and quenched with 
saturated aqueous Na2SO (2 mL) and the two phases were 
separated. The aqueous layer was extracted with CHCl (2x5 
mL) and the combined extracts were washed with brine (5 
mL), dried (Na2SO4) and conc. in vacuo to give a pale yellow 
solid. The crude product was dissolved in toluene (2 mL) and 
solid NaHCO (15 mg) was added. The mixture was heated at 
reflux for 2 huntil all the intermediate sulfoxide had been 
consumed. The reaction was diluted with water (10 mL) and 
extracted with CHCl (3x5 mL). The combined extracts 
were washed with brine (5 mL), dried (NaSO) and conc. in 
vacuo to give a pale yellow syrup. The crude product was 
purified by column chromatography (SiO, 50% EtOAc/hex 
anes) to yield a colorless syrup (14 mg.87% yield). R, 0.60 
(40% EtOAc/Hexanes). IR (thin film) 3446, 2978, 2932, 
2868, 1684, 1489, 1435, 1321, 1227, 1170, 1147, 1054 cm. 
'HNMR (300 MHz, CDC1) & 6.94 (1H, s), 5.77 (1H, d, J=8.8 
Hz), 5.30 (1H, dd, J–6.6, 1.5 Hz), 5.02 (Major rotamer 0.60H, 














4.14 (2H, q, J=7.2 Hz), 3.84 (3H, s), 2.96-2.84 (2H, m), 
2.78-2.66 (3H, m), 2.60-2.52 (1H, d, J-21 Hz), 2.45-2.41 
(1H, m), 1.95-1.87 (4H, m), 1.27 (3H, t, J–7.2 Hz); 'CNMR 
(75 MHz, CDC1) Major rotamer: 6155.3, 145.9, 143.3, 
134.4, 131.3, 126.9, 125.5, 116.2, 113.3, 91.4, 66.0, 56.4, 
50.3, 47.8, 43.8, 39.3, 37.2, 35.3, 29.7, 14.6; Minor rotamer: 
& 155.0, 145.9, 143.3, 134.7, 131.3, 126.8, 125.3, 117.7, 
113.5, 91.4, 61.7, 56.8, 49.9, 47.8, 41.1, 39.7, 37.7, 34.9, 29.9, 




To the allylic alcohol 23 (10 mg, 0.023 mM), in THF (1.5 
mL) was added LiAlHa (2M in THF, 0.3 mL) and the solution 
was stirred at 25°C. for 6 h. The reaction mixture was cooled 
to 0°C. and quenched with drop-wise addition of saturated 
aqueous NaSO (0.5 mL). The salts were filtered over a pad 
of Celite and washed with diethyl ether (10 mL). The com 
bined organics were dried (Na2SO4) and evaporated in vacuo 
to yield a pale yellow solid. The crude product was purified 
(SiO, 10% MeOH/CHCl) to give codeine (6 mg, 87%). 
R-021 (10% MeOH/CH.C.). Mp. 151-153°C. IR (thin 
film) 3400, 2925, 1501, 1451 cm. "H NMR (300 MHz, 
CDC1) & 6.66 (1H, d, J=8.4 Hz), 6.57 (1H, d, J=8.4 Hz), 5.71 
(1H, d, J=10 Hz), 5.29 (1H, dt, J=10, 2.7 Hz), 4.90 (1H, dd, 
J=6.6Hz), 4.18 (1H, m), 3.84 (3H, s), 3.36 (1H, m), 3.05 (1H, 
d, J–18.4 Hz), 2.69(1H, s), 2.60 (1H, dd, J=12, 4.4 Hz), 2.45 
(3H, s), 2.40 (1H, dd, J=12.4, 3.5 Hz), 2.31 (1H, dd, J=18.4, 
6 Hz), 2.03-2.12 (1H, m), 1.88 (1H, d, J=12.8 Hz); 'C NMR 
(75 MHz, CDC1) & 146.2, 142.0, 133.3, 130.8, 127.9, 126.8, 
119.3, 112.7, 91.2, 66.3, 58.8, 58.7, 56.1, 46.3, 42.8, 40.4, 




To a solution of codeine 4 (8 mg, 0.026 mM) in chloroform 
(2.5 mL) was added borontribromide (1.0 M in CHCl, 0.20 
mmol) dropwise over 1 min and the resulting mixture was 
stirred at room temperature for 20 min. A solution of NHOH 
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(10% aq., 3 mL) was added dropwise at 0°C. The mixture was 
repeatedly extracted with a solution of 9:1 CHC1/EtOH 
(4x15 mL) and the combined organics were washed with 
brine (25 mL), dried (NaSO) and concentrated in vacuo. 
The crude product was purified (SiO, 10% MeOH/CHC1,) 5 
to give morphine 5 (6.5 mg, 86% yield) as a white solid. 
R-0.06 (10% MeOH/CH,Cl). Mp. 251-255° C. IR (thin 
film) 3352, 2924, 1459, 1249 cm. H NMR (300 MHz, 
CDC1) & 6.62(1H, d, J=8.1 Hz), 6.48 (1H, d. J=8.1 Hz), 5.67 
(1H, d, J=9.9 Hz), 5.27 (1H, dt, J=9.9, 2.6 Hz), 4.84 (1H, dd, 
J=6.3 Hz), 4.18 (1H, m), 3.84 (3H, s), 3.36 (1H, m), 3.03 (1H, 
d, J=18.6 Hz), 2.66 (1H, m), 2.60 (1H, d, J–4.5Hz), 2.47 (1H, 
dd, J=24.3, 3.6 Hz), 2.46 (1H, s), 2.34 (1H, dd, J=18.9, 6.3 
Hz), 2.06 (1H, dt, J=12.9, 5.1 Hz), 1.90 (1H, d, J=12.9 Hz). 
'C NMR (75 MHz, CDC1) & 145.6, 138.1, 132.7, 130.4, 
127.9, 125.5, 119.5, 11.6.8, 91.1, 66.2, 58.7, 46.2, 42.7, 42.4, 
40.0, 34.8, 20.4. HRMS calcd. for CHNO (MH) 




Acid catalyzed hydrolysis of 14 using 2M HCl in dioxane 
heated at reflux resulted in 24 (93%, 87.5% from 8, structure 
by X-ray), FIG. 3B then FIG. 7B. Reductive amination of 24 25 
with MeNH. (1.2eq)/THF (0.25 M)/NaBH(OAc) (3.2 eq)/ 
AcOH (5x) at 60° C. proceeded sequentially to give first 25, 
followed by the carbinolamine 26, and lastly (+)-narwedine 2 
(74%) in a single reaction pot. 
Compounds 2, 14, 24, 25 and 26 are racemates, but the 30 
structures are drawn in FIGS. 7A & B (for clarity) as a single 
enantiomer with their configuration corresponding to that of 
(-)-galanthamine. 
Since (E)-narwedine has been converted into (-)-galan 
thamine 1 by spontaneous resolution followed by L-Selec- 35 
tride reduction in virtually quantitative yield, this completes 
the synthesis in an overall yield of 64.8% which is approxi 
mately five times the yield of the current commercial process. 
Example V 40 
Acid catalyzed hydrolysis of 14 (FIG.3B) using 2M HCl in 
dioxane heated at reflux resulted in 24 (93%, 87.5% from 8, 
structure by X-ray), FIG. 3B then FIG. 7C. Reductive ami 
nation of 24 with MeNHC1/NEtPr/dioxane and NaCNBH/ 4s 
AcOHat 23° C. for 5h proceeded to give 27, followed by the 
treatment with 1M MeSOH under dioxane at 80° C. for 40 
minutes to yield (t)-narwedine 2 (74%) in a single reaction 
pot. 
Compounds 2, 14, 24, and 27 are racemates, but the struc- so 
tures are drawn in FIG.7C (for clarity) as a single enantiomer 
with their configuration corresponding to that of (-)-galan 
thamine. 
Since (E)-narwedine has been converted into (-)-galan 
thamine 1 by spontaneous resolution followed by L-Selec- ss 
tride reduction in virtually quantitative yield, this completes 
the synthesis in an overall yield of 64.8% which is approxi 
mately five times the yield of the current commercial process. 
We claim: 60 
1. A method of preparing a cross-conjugated 2.5-cyclo 
hexadienone, comprising: 
a) providing a Substituted biphenyl: 
b) treating said biphenyl under conditions so as to create a 
substituted biphenyl ether; 65 
c) treating said ether under conditions so as to create a 
cross-conjugated 2,5-cyclohexadienone. 
68 
2. The method of claim 1, wherein said substituted biphe 
nyl of step a) is obtained under Suzuki coupling conditions. 
3. The method of claim 1, wherein said substituted biphe 
nyl of step a) is obtained under Ullman coupling conditions. 
4. The method of claim 1, wherein said substituted biphe 




Z is H or —O R, wherein 
R is an alkyl, aryl, alkanediyl, alkynyl, arenediyl, aralkyl, 
heteroarenediyl, heteroaralkyl, heteroaryl, alkenyl, alk 
enediyl, alkynediyl, acyl, alkylidene, or a Substituted 
version of any of these groups, or a protecting group, 
with the proviso that R is not H: 
and wherein 
R is H or a protecting group. 
5. The method of claim 4, wherein said protecting group is 
selected from the group consisting of triisopropylsilyl and 
tert-butyldimethylsilyl, and SiRRRs where R. R. and Rs. 
can be alkyl, alkanediyl, alkynyl, aryl, arenediyl, aralkyl, 
heteroaryl, heteroarenediyl, heteroaralkyl, or a substituted 
version of any of these groups. 





wherein Z is H or RO, wherein R is an alkyl, aryl, or 
heteroaryl group or a protecting group, but not H; R is 
a protecting group or H; R can be alkyl, alkanediyl. 
alkynyl, aryl, arenediyl, aralkyl, heteroaryl, heteroare 
nediyl, heteroaralkyl, or a substituted version of any of 
these groups; and X is a halide or an equivalent leaving 
group. 
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7. The method of claim 1, wherein said cross-conjugated 





wherein R is an alkyl, alkanediyl, alkynyl, aryl, arenediyl. 
aralkyl, heteroaryl, heteroarenediyl, heteroaralkyl, or a 
Substituted version of any of these groups or a protecting 
group but not H; and R is a protecting group or H. 




wherein Z is Hor RO, wherein R is an alkyl, alkanediyl. 
alkynyl, aryl, arenediyl, aralkyl, heteroaryl, heteroare 
nediyl, heteroaralkyl, or a substituted version of any of 
these groups or a protecting group, but not H; R is a 
protecting group or H; R can be alkyl, alkanediyl, alky 
nyl, aryl, arenediyl, aralkyl, heteroaryl, heteroarenediyl. 
heteroaralkyl, or a substituted version of any of these 












wherein Z is Hor RO, wherein R is an alkyl, alkanediyl. 
alkynyl, aryl, arenediyl, aralkyl, heteroaryl, heteroare 
nediyl, heteroaralkyl, or a substituted version of any of 
these groups or a protecting group, or H; and R is a 
protecting group. 
10. A compound of the formula: 
HO CHO 
OR 
wherein Z is Hor RO, wherein R is an alkyl, alkanediyl. 
alkynyl, aryl, arenediyl, aralkyl, heteroaryl, heteroare 
nediyl, heteroaralkyl, or a substituted version of any of 
these groups or a protecting group, but not H; R is a 
protecting group. 
k k k k k 
